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Summary  
Tuberculosis (TB) caused by Mycobacterium tuberculosis (MTB), remains a challenging disease, 
killing more people today than any other bacterial infection. The problem has further been 
compounded by the emergence of multi-drug resistant (MDR) and extensively drug-resistant (XDR) 
TB. Through standardized DNA fingerprinting methods, insight is gained into the disease dynamics 
thereby enabling investigations of transmission patterns and strain properties such as drug 
resistance.  
 
The aims of this study were to determine the genetic diversity of drug susceptible and drug resistant 
MTB strains in Johannesburg and to potentially identify a predominant clone circulating in the area. 
Johannesburg is the most populated, densely inhabited industrialized city in South Africa and it is 
likely that the introduction and spread of mycobacterial strains is not the same as seen in other 
major African cities.  
 
Isolates (n=500) were collected from the NHLS Mycobacteriology (TB) Culture Referral 
Laboratory. The isolates originated from patients residing in the seven regions (Regions A, B, C, D, 
E, F and G) of Johannesburg suspected for drug-resistant TB who had submitted specimens for 
routine culture and susceptibility testing according to the national TB control programme of 
Republic of South Africa. These isolates were typed using spoligotyping and IS6110 RFLP.  
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Spoligotyping results showed a wide genetic diversity of strains circulating in the Johannesburg 
area with eight shared types [Beijing (SIT 1), S (SIT 34), LAM4 (SIT 60), T1 (SIT 53), LAM3 (SIT 
33), H3 (SIT 50), EAI1_SOM (SIT 48) and X3 (SIT 92)] from 340 isolates being the most 
prevalent. This indicates that TB incidences in Johannesburg are not due to clonality but rather due 
to diversity of strains, with Beijing SIT 1 isolates being the most predominant at (n = 135) 27%. 
There is a considerably high relationship between the eight predominant families and drug-
resistance with a P value of <0.001. The Beijing SIT 1 and LAM 4 SIT 60 (F15/LAM4/KZN) 
genotypes were found to contribute significantly to drug-resistant incidences in Johannesburg. Of 
the 135 isolates of Beijing SIT 1, 52% were associated with drug-resistance while 93% of the LAM 
4 SIT 60 (F15/LAM4/KZN) isolates were associated with drug-resistance, with 54% of the later 
being XDR. Through data comparison, it was noticed that Beijing SIT 1, LAM4 SIT 60 and LAM3 
(SIT 33) genotypes are more prevalent in South Africa than any other African country. 
Furthermore, the study did not identify other families such as LAM10-CAM (SIT 61) and T2-U 
which dominate in other African countries such as Cameroon, Nigeria and Uganda. There is 
geographical specificity of the isolates which would be expected to have an impact on TB 
epidemiology.  
 
 
A subset of isolates from spoligotyping clusters were analyzed by IS6110 RFLP technique. Thirty 
distinct RFLP patterns were revealed from 74 MTB isolates and results showed highly variable 
IS6110 fingerprinting patterns.  The common fingerprinting patterns found in this study were the 
F29, F15, F28 and F11. Of the thirty obtained RFLP fingerprint patterns, 15 (20%) were 
represented by a single isolate from which 3 (4%) had zero copy number. The clustering percentage 
viii 
 
of the isolates was considerably high at 80% (59/74), which may suggest cases representative of 
recent transmission, while the 15 unique isolates may indicate epidemiological independence or 
recurrent infection. Comparison of the results for the two methods showed that 56 isolates had 
identical IS6110 RFLP patterns as well as spoligotypes. This study has demonstrated the usefulness 
of spoligotyping technique in genotyping the MTB isolates containing a low copy number of 
IS6110 between zero and six. Potential ongoing transmission of TB, as evidenced through a high 
strain cluster rate by both methods, necessitates the evaluation of TB monitoring policies in the area 
and urges the implementation of appropriate infection control measures in order to minimize the 
spread of the disease. 
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Chapter one: Introduction 
 
1.0 General Introduction 
 
1.1 The history of tuberculosis 
 
Tuberculosis (TB) is a common, and in many cases lethal, infectious disease caused by various 
species of the Mycobacterium tuberculosis complex (MTBC), usually Mycobacterium 
tuberculosis (MTB) (Smith 2003b; Glickman et al. 2001; Vasconcellos et al. 2010). The origin 
of MTB has been the subject of much investigation and it is thought that the bacteria in the genus 
Mycobacterium, like other actinomycetes, were initially found in soil and that some species 
evolved to live in mammals (Smith, 2003).  TB has plagued humankind throughout history and 
human prehistory. Modern techniques of molecular genetics and genomic sequencing of several 
strains of MTB allow a more rigorous estimation of the time of origin of MTB to be more than 
150 million years ago (Daniel, 2006). This is seen through evidence of spinal disease found in 
Egyptian mammals of several thousand years BC as well as in the reference found in ancient 
Babylonian and Chinese writings (Ahmad, 2011a; Daniel, 2006). There are other well 
documented cases of TB disease such as bone TB, including Pott‟s disease in Peruvian 
mummies, and the availability of abundant archaeological evidence in Columbia from the 
Andean Region which shows that the disease occurred throughout the hemisphere prior to the 
arrival of the first European explorers, while modern strains of MTB appear to have originated 
from a common ancestor approximately 15, 000 - 20,000 years ago (Daniel, 2006).  
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The history of TB was changed dramatically on 20 March 1882, when Hermann Heinrich Robert 
Koch made his justly famous presentation, “Die Aetiologie der Tuberculose”, to the Berlin 
Physiological Society in which he elucidated the aetiological agent of TB by identifying the 
tubercle bacillus (Daniel, 2006). Unfortunately, TB is still one of the most prevalent infections of 
humankind and a formidable public health challenge that shows little sign of abating (Ahmad, 
2011a).  
 
 
WHO has prioritized to improve TB diagnosis, treatment, and vaccination, as well as 
development of new tools to control and fight the epidemic as it aims to eliminate TB by 2050 
(WHO report, 2010). Understanding disease dynamics is one way to achieve controlling the 
disease epidemic. The discovery of polymorphic DNA in MTB has led molecular typing to 
become a variable tool for the study of the disease dynamics. Phenotypic methods such as Phage 
typing has been used to type MTB, unfortunately, this method has a low discriminatory power 
due to its failure to discriminate between two unrelated strains of MTB as well as the inability to 
detect laboratory cross contamination is a major setback. This triggered the development of more 
sophisticated typing methods to study the disease dynamics and its epidemiology. In the early 
1980s, under the influence of advances in molecular biology, DNA-based typing methods were 
developed with improved discriminatory power over phenotypic methods (Schürch & Van 
Soolingen 2012; Lopez-Alvarez et al. 2010). 
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The effective strain genotyping techniques like IS6110 DNA fingerprinting, the PCR based 
spoligotyping technique, and most recently mycobacterial interspersed repetitive unit-variable of 
number of tandem repeats (MIRU-VNTR) analysis have been established to analyze diversity 
and population structure of clinical MTBC and MTB strains (Homolka et al. 2008). Molecular 
typing classifies the MTB strains into lineages which provides insight into the genetic diversity 
of the strains being investigated and helps identify the predominant genetic groups in a 
population (Shabbeer et al. 2012). Recent reports indicate that genetic heterogeneity of MTB 
strain is higher than previously anticipated and may influence host pathogen interaction, 
immunogenicity, transmissibility, development of drug resistance, and the performance of 
diagnostic tests. This depicts the importance of  genotyping the MTB strains in a community 
(Homolka et al. 2008). Further discussion of molecular background and techniques is continued 
in chapter one section 1.8, chapter two and chapter three.  
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1.2 Mycobacterium tuberculosis 
 
1.2.1 Classification of Mycobacterium tuberculosis 
 
Mycobacterium tuberculosis falls in the taxonomical group (phylum) of Actinobacteria under the 
genus of Mycobacterium (Figure 1.1) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.1: Phylogenetic tree of Mycobacterium tuberculosis. 
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1.2.2 Mycobacterium Tuberculosis Complex  
 
There are eight MTBC species which can cause tuberculosis disease. The eight species are; 
Mycobacterium tuberculosis, Mycobacterium africanum, Mycobacterium bovis BCG, 
Mycobacterium microti, Mycobacterium canetti, Mycobacterium tuberculosis caprae, dassie 
bacillus and the recently discovered Mycobacterium tuberculosis pinipedii. (Lawn & Zumla 
2011; Vasconcellos et al. 2010; Mostowy et al. 2002). 
 
The group of bacteria in MTBC are characterized by 99% similarity at the nucleotide level and 
identical 16S rRNA sequences but differ widely in terms of their host tropism, phenotypes, 
certain physiological features, biochemical features and pathogenicity (Chernick, 2004). 
Therefore, it is believed that the members of the MTBC are the clonal progeny of a single 
successful ancestor, resulting from a recent evolutionary bottleneck that occurred 20,000 to 
35,000 years ago and the MTBC members, all agents responsible for TB, are considered to be 
the most successful human pathogen (Gutierrez et al. 2005).  The MTB is the most common 
member within the complex to cause human tuberculosis, and thus the focus of this paper. 
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1.2.3 Cell Biology of Mycobacterium tuberculosis  
 
 
MTB is an aerobic, non-motile, non-encapsulated, non-spore forming and distinctive rod shaped 
bacillus (Figure 1.2). It grows most successfully in tissues with high oxygen content, such as the 
lungs. Compared with the cell walls of the other bacteria, the lipid-rich cell wall is relatively 
impermeably to basic dyes unless combined with phenol. Thus MTB is neither gram positive nor 
gram negative but is instead described as acid-fast, since once stained it resists decolourisation 
with acidified organic solvents.  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.2: Mycobacterium tuberculosis is a non-motile, non-encapsulated, distinctively rod shaped 
bacillus. Adapted from Dahl, 2004. 
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In addition to the lipids, the cell wall also contains a remarkable mixture of polypeptides, 
lipoglycans and glycolipids in its waxy envelope layers (Figure 1.3) (Ventura et al. 2007).  MTB 
is a slow growing organism with replication occurring every 15 to 20 hours. This slow 
replication rate together with the ability to persist in a latent state results in the need for long 
duration of both drug therapy for TB and preventive therapy in people with MTB infection 
(Lawn & Zumla, 2011; Glickman et al.  2001). 
 
 
 
Figure 1.3: Schematic diagram of the Mycobacterium tuberculosis cell wall. Adapted from Abdallah et 
al. 2007 
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1.3 Transmission of Mycobacterium tuberculosis and contributing factors 
 
1.3.1 Transmission of Mycobacterium tuberculosis 
 
TB is a communicable disease and patients with pulmonary or laryngeal TB are the most 
important source of infection. Infection is initiated by inhalation of droplet nuclei, which are 
particles of 1-5ụm in diameter containing MTB. These droplets are expectorated by patients with 
active pulmonary TB, typically when the patient coughs, sneezes, speaks, or sings and since the 
droplet nuclei are very small, they can remain in the air for several minutes to hours (Standards, 
2000; Ahmad, 2011a).  The MTB containing droplet nuclei traverse the mouth, the nasal 
passage, the upper respiratory tract and the bronchi to reach the alveoli of the lungs.  The risk of 
infection is dependent on several factors such as the infectiousness of the source case, the 
closeness of the contact, the bacillary load inhaled, and the immune status of the potential host 
(Ahmad, 2011a).  
 
1.3.2 Contributing factors for TB transmission 
 
 
The current TB epidemic is being sustained and fuelled by two important factors namely the 
Human Immunodeficiency Virus (HIV) epidemic and its association with TB disease and the 
increasing rates of drug resistant TB. Other contributing factors include population expansion, 
poor case detection and cure rates in impoverished countries, active transmission in overcrowded 
hospitals, prisons, and other public places, migration of individuals from high-incidence 
countries due to wars or famine, drug abuse, social decay, and homelessness (Ahmad, 2011a). 
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1.3.2.1 TB and HIV 
 
 
Human Immunodeficiency Virus (HIV) and TB are interacting epidemic diseases (Kantipong et 
al. 2012). Starting in the 1980s, the HIV epidemic led to a major upsurge in TB cases and TB 
mortality in many countries  (WHO  global TB report, 2011). HIV infected people are at an 
increased risk of acquiring MTB infection and to an increased risk of progressing to active TB 
disease. (Kantipong et al. 2012). HIV and TB coinfected individuals are approximately 21 to 34 
times more likely to develop TB disease when compared with those who are HIV negative 
(WHO global report, 2011). Globally, just over one in ten of the almost nine million people who 
develop TB each year are HIV positive, which equates to 1.1 million new TB cases among 
people living with HIV in 2010.  In the African region, this accounted for 82% of the new TB 
cases that were living with HIV in 2010 and 79% of new TB cases that were living with HIV in 
2012. An estimated 900 000 (39%) of the 2.3 million people who developed TB in 2010 were 
HIV-positive from which 0.4% million deaths occurred (WHO global report, 2011; WHO global 
report, 2012). 
 
1.4 Pathogenesis of Mycobacterium tuberculosis 
 
 
Infection with MTB starts with the phagocytosis of the bacilli that have reached the alveoli, 
antigen-presenting cells such as alveolar macrophages and dendritic cells (Ahmad, 2011a). 
Although the majority of these bacilli are destroyed, a small number may replicate within the 
alveolar macrophages (Glickman, et al. 2001). Once the macrophages die, the bacilli can spread 
via the lymphatic system or bloodstream to more distant sites, such as the brain and bone and this 
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is termed miliary TB (Rastogi et al. 2001; Ray et al. 2013). The dissemination of TB from the 
lungs to other parts of the body leads to the development of extrapulmonary TB (EPTB) such as 
bone TB and central nervous system (CNS) TB (Ray et al. 2013; Thwaites et al. 2009). The 
ability of the bacilli to grow inside phagosomes and phagolysosomes, as well as to inhibit the 
fusion of bacteria-containing phagosomes with lysosomes upon macrophage infection, is the 
main strategy to evade the immune system and disseminate the organism (Rastogi et al. 2001). 
MTB has no known endotoxins or exotoxins and therefore; there is no immediate host response 
to infection. In the vast majority of the infected individuals, an effective cell-mediated immune 
response develops 2-8 weeks after infection that stops further multiplication of the tubercle 
bacilli. The establishment of an infection in the lungs depends on both the bacterial virulence and 
the inherent microbicidal ability of the alveolar macrophage (Standards, 2000;  Ahmad, 2011a).  
  
1.4.1 Latent TB Infection 
 
 
In persons with an intact cell-mediated immunity, granulomas will form due to collections of 
activated T lymphocytes, macrophages and other immune cells (Figure 1.4). The formed 
granulomas will wall off the growing necrotic tissue, hence limiting further replication and 
spread of the tubercle bacilli. While inside granulomas, the bacilli may either die or survive and 
assume a non-replicating state, which is referred to as latent tuberculosis infection (LTBI). The 
bacilli can stay in this non-replicating state for decades until the immune system wanes. 
Antibodies against MTB are formed during this time but do not appear to be protective. The 
evidence of infection at this stage may be defined by immunological sensitization such as  
Tubercle Skin Test (TST) and interferon-gamma release assays (IGRA) (Standards, 2000; 
Ahmad, 2011a). 
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         Figure 1.4: Formation of granulomas from Mycobacterium tuberculosis. Adapted from Vyas 2012. 
 
Several features such as HIV infection, malnutrition, drug use, cancer, diabetes, chronic renal 
insufficiency and immunosuppressive drug therapy may alter the course of latent TB (LTB) 
(Table 1.1) and influence the development of active disease (Parrish et al. 1998). It is estimated 
that approximately 10% of individuals with LTB infection (who are not further compromised by 
the above-mentioned comorbid diseases) that are not given preventive therapy, will develop 
active tuberculosis but in those with comorbid diseases it is higher than 10% (Standards, 2000).  
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Table 1.1: Proposed framework of potential outcomes of the host-pathogen relationship following 
exposure to MTB infection. Source:  Lawn, et al. 2011 
 
  
 
 
Terminology 
 
 
T cell 
priming 
 
 
Mycobacterial 
numbers 
 
 
 
Symptoms 
 
Impact of 
HIV 
infection 
  
Impact 
of 
ART 
 
1 
Infection eliminated by 
innate immune system 
 
 
Innate 
Immune 
 
     _ 
 
      _ 
 
      _ 
 
 
 
 
2 
Infection eliminated by 
acquired immune 
response 
 
 
 
Acquired 
immune 
 
 
      
     + 
 
      
       _ 
 
       
       _ 
 
 
3 
Infection occurs but 
remains under immune 
control 
 
 
 
Quiescent 
infection 
 
 
      
      + 
 
 
      
       + 
 
       
      _ 
 
 
4 
Active bacterial 
replication but remains 
subclinical 
 
 
 
Active 
infection 
 
 
      
       + 
 
 
      
      +++ 
 
       
       _ 
 
 
5 
Uncontrolled bacterial 
replication and clinical 
TB disease 
 
 
 
TB disease 
 
 
 
      + 
 
 
 
    +++++ 
 
 
 
      ++ 
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1.5. Disease presentation and diagnosis  
 
1.5.1 Disease presentation 
 
 
Clinical manifestations of TB are quite variable and depend on a number of factors. Prior to the 
HIV epidemic, approximately 85% of reported TB cases were limited to the lungs, with the 
remaining 15% involving either exclusively only non-pulmonary or both pulmonary and 
nonpulmonary sites. This situation has now changed mainly in HIV infected individuals who 
may present with TB disease localized in pulmonary or extrapulmonary sites or both (Standards, 
2000).  Signs and symptoms of pulmonary TB include a cough for at least two weeks, fever, 
chills, night sweats, unexplained weight loss, haemoptysis and fatigue. In contrast signs and 
symptoms of EPTB depend on the site of disease (Steingart et al. 2013).  
 
 
1.5.2 Diagnosis of Tuberculosis 
 
1.5.2.1 TB Microscopy 
  
 
Efficient TB control is based on an early diagnosis followed by the rapid identification of drug 
resistance, to ensure adequate treatment of patients to break the chain of transmission and avoid 
the spread of resistant strains (Lacoma et al. 2012a). In spite of modern advances, microscopy 
remains a cornerstone of TB control because it identifies smear microscopy positive (most 
infectious) cases and is rapid and affordable, although has a limited specificity ( Drobniewski et 
al. 2003). In most countries, smear microscopy through Ziehl-Neelsen (ZN) acid-fast stain 
continues to be the primary method for diagnosing TB and will remain to be favored mostly in  
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low income and high TB prevalence countries as it provides most of the essential laboratory-
epidemiological indicators needed for the evaluation of the National TB Programme (NTP) 
Page-shipp et al. 2010; Drobniewski et al. 2003).   While cheap and relatively easy to perform, 
the method is insensitive and performs poorly in HIV infected patients. It requires ≥ 5000 
bacilli/ml of sputum to achieve a positive result. In addition, the procedure requires the 
observation of 100 to 300 fields in order to obtain accurate results. It detects 75% of all people 
who have active pulmonary TB (PTB) (Dawson, 2000; Page-shipp et al. 2010; Drobniewski et 
al. 2003).   Fluorescence microscopy with fluorochrome dyes such as auramine O or auramine-
rhodamine is considered to be a more sensitive test than ZN smear for the diagnosis of TB. 
However, the procedure is more expensive than the conventional method as it requires unstable 
and expensive fluorescent staining reagents including expensive equipment (Patino et al. 2008).  
 
 
1.5.2.2 TB Diagnosis through solid and liquid culture 
 
 
Mycobacterial culture is generally considered the best available diagnostic test for the 
microbiological TB diagnosis and is the first step in detecting drug resistance. Culture is a more 
sensitive test than smear microscopy for the detection of MTB since it can detect as few as 10 to 
100 viable bacteria/ml. Culture is recognized as being critically important in detecting TB, 
mainly in HIV-positive individuals who often have low bacillary loads in sputum. However, the 
procedure is not routinely performed in resource poor countries (Steingart et al. 2013) where 
coinfection of HIV/TB is high. It is also a relatively complex and slow procedure. It requires 
specialized laboratories and highly skilled staff (Parsons et al. 2011; Steingart et al. 2013).  
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Solid culture (LÖwenstein Jensen [LJ] medium, Middlebrook solid agar), typically takes four to 
eight weeks for results whereas liquid cultures (Middlebrook liquid broth, BackTAlert 
[BioMerieux] medium and Mycobacteria Growth Indicator Tube® [Becton Dickson, Sparks, 
USA] [MGIT]) though more rapid than solid culture, still requires an average of seven days for 
the results (Dionne et al. 2007; Bardarov et al. 2003). These phenotypic methods may also be 
used to detect drug resistant MTB. In addition, liquid culture is hampered with higher rates of 
contamination (Rodrigues et al. 2009). 
 
 
Lack of culture diagnostic services in high-burden countries, has seen programmes often employ 
diagnostic algorithms, which require that TB suspects with a negative smear are first treated with 
antibiotics which are ineffective against TB. Only after this treatment has failed (or in critically 
ill patients) is TB treatment started (Borgdorff et al. 2002). This may lead to development of 
drug resistance and increased mortality rate.  
 
1.5.2.3 TB Diagnosis through molecular techniques 
 
 
Although conventional microbiology methods still constitute the principal tool for the diagnosis 
of TB, direct microscopy testing has low sensitivity and culture requires long culturing time. 
This often leads to considerable delays, compromising patient care and outcomes. Nucleic acid 
amplification tests (NAAT) for rapid TB diagnosis are increasingly becoming available and 
being utilized to provide a more rapid TB diagnosis (Lawn & Zumla, 2012; Sala et al. 2008). 
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1.5.2.3.1 GeneXpert® MTB/RIF assay (Cepheid Inc., CA, USA) 
 
The GeneXpert
®
 is a multifunctional, automated diagnostic platform. Through real-time 
Polymerase Chain Reaction (PCR) the diagnosis of TB and simultaneous assessment of 
rifampicin (RIF) resistance is made (Lawn & Zumla, 2012; Carlton, 2011). The test procedure 
may be used directly on raw sputum samples or sputum pellets. The assay limit of detection is 5 
genome copies of purified DNA per reaction or 131 colony forming units (CFU) per ml of MTB 
spiked sputum. Through the use of molecular beacon technology RIF resistance TB is detected. 
These nucleic acid probes recognize and report the presence or absence of the „wild type‟ (RIF-
susceptible) sequence of the 81 base pair rpoB gene of MTB (Steingart et al. 2013).   
 
 
The GeneXpert detects MTB in >98% of smear positive, culture positive specimens (Scott et al. 
2011). Although the GeneXpert can detect resistance to RIF, which is regarded as a marker of 
MDR, it cannot diagnose MDR-TB (which is defined as MTB resistant to isoniazid (INH) and 
RIF, with or without resistance to other first-line drugs). Culture and drug susceptibility testing 
(DST) to confirm RIF resistance and testing for resistance to isoniazid and other first and 
second-line drugs is recommended once rifampicin resistant TB has been detected         
(Steingart et al. 2013). The use of the GeneXpert in the diagnosis of EPTB has recently been 
endorsed by the WHO (WHO recommendations, 2013). 
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1.5.2.3.2 GenoType MTBDR plus and MTBDRsl (Hain Lifesciences) 
 
The standard methods for detecting extensively drug-resistant MTB (XDR – defined as MTB 
resistant to at least INH and RIF as well as to any fluoroquinolone, and at least to one of the 
three injectable drugs; amikacin (AMK), capreomycin (CPM), and kanamycin (KM) (Lacoma et 
al. 2012) are not only difficult but time consuming as mentioned earlier. Modern broth-based 
culture systems, such as MGIT 960 (Becton Dickinson, Cockeysville, MD) or BacT/ALERT 3D 
(bioMerieux, Durham, NC), are somewhat quicker but are expensive and need sophisticated 
equipments. Molecular tests such as MTBDRplus and MTBDRsl probe assays (Hain Lifescience 
GmbH, Nehren Germany) do provide results within a day or two and thus enable for early and 
appropriate treatment of the drug-resistant cases which will reduce morbidity and mortality of 
MDR-TB cases and also interrupt transmission of drug-resistant TB strains (Gupta et al. 2013). 
 
 
The GenoType MTBDRplus detect mutations in the inhA, katG, and rpoB genes that confer INH 
and RIF resistance. It is a DNA strip assay which uses PCR and hybridization to detect mutations 
(Anek-vorapong et al. 2010). Multiple reports have shown that the performance of the Genotype 
MTBDRplus assay in terms of sensitivity and specificity closely resembles that of conventional 
culture-based identification and susceptibility testing and its potential applications in laboratory 
diagnosis of drug-resistant TB have been widely validated (Zhang et al. 2011; Barnard et al. 
2008; Huang et al. 2009). 
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The Genotype MTBDRsl assay uses multiplex PCR and reverse hybridization to identify MTB 
and relevant mutations in the gyrA, rrs and embB genes, which confer resistance respectively to 
fluoroquinolone (FQ), CPM, AMK, KM and Ethambutol (EMB) (Ehlers, 2012). This assay was 
developed for the rapid detection of MTB resistance against second-line drugs. Studies have 
shown that the assay has a high accuracy for FQ, amikacin and capreomycin resistance detection 
in clinical isolates despite its failure to detect all mutations in these genes, which is why results 
require confirmation by culture based DST methods (Kiet et al. 2010; Felkel et al. 2013). 
 
 
1.6. Treatment of tuberculosis and development of drug-resistance 
 
1.6.1 Treatment of Tuberculosis 
 
 
In the first half of the 20
th
 century, the disease was considered incurable after sulfonamides and 
Penicillin antibiotics showed no useful activity against MTB and the lipid-rich cell wall was 
believed to make chemotherapy impossible (Gillespie, 2002). The effective treatment of TB 
started in 1946 with the introduction of streptomycin (SM) (Mitchison & Davies, 2012) as 
monotherapy which rapidly dispersed the first hopes of a conquest of TB. Although patients on 
therapy improved compared to those not on therapy, relapse occurred in many patients and the 
organisms were found to be resistant to SM. The combined prescription of INH, pyrazinamide 
(PZA), RIF, EMB, and other drugs brought cure rates of over 95% and shortened treatment time 
from 2 years to 6 months. This gave the medical community the basic tools for TB control 
(Gillespie, 2002). 
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TB can be treated with either first-line drugs which are used to treat susceptible TB or second-
line drugs which are used to treat resistant TB. The most common second line drugs are CPM, 
KM, AMK, Ethionamide (ETHIO), para-aminosalicylic acid (PAS), Ofloxacin (Ofxn), 
Ciprofloxacin (Cpfxn), Cycloserine (Csn), Levofloxacin (Lflxn), and Clofazimine (Cfmn). The 
downfall with the second-line drugs is that they are inherently more toxic and less effective than 
the first-line drugs and the use of second-line drugs require a prolonged period (9 months) as 
opposed to the six months with first-line drugs (Raja et al., 2010).  
 
 
A combination of multiple TB drugs is necessary. MTB grows in different locations in the 
human body: pulmonary cavities, pleural cavity pus and solid caseous material within 
granulomas. Each of the antituberculosis drugs has a major role in dealing with one of these 
populations. INH is active mainly against the organisms growing aerobically in pulmonary 
cavities. It is critical early in therapy as its bactericidal activity rapidly reduces the sputum viable 
count. PZA is only active at a low pH, making it ideally suitable for killing the organisms inside 
the phagosome. This explains the finding that PZA appears to have no benefit after the second 
month of therapy (Raja, 2010; Zhang et al. 2003; Mitchison & Davies 2012). RIF is important in 
killing organisms that are metabolizing slowly, killing the “persisters”, and sterilizing the 
patient‟s sputum (Gillespie 2002).  
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1.6.2. Development of drug-resistance 
 
Despite the availability of chemotherapy against the tubercle bacillus and the implementation of 
DOT, drug-resistant TB is still emerging (Johnson et al. 2003). The prolonged treatment regimen 
could be the additional contributing factor (Mitchison & Davies, 2012). With the rather unusual 
biological characteristics of this pathogen, the disease shows a distinctive natural history and a 
very slow response to existing chemotherapeutic agents (Chang et al. 2011).  
 
MDR-TB/XDR-TB seems to be a man made phenomenon that has emerged because of improper 
TB treatment. MDR-TB has emerged since INH and RIF were used in the 1970s. Increasing the 
use of FQ in TB treatment in the 1990s promoted the development of pre-XDR-TB and XDR-
TB. In comparison with drug-susceptible TB, MDR-TB and XDR-TB are more difficult to treat 
(Chang & Yew, 2013).  
 
Risk factors for MDR- and XDR-TB seems to be non-adherence to treatment, development of 
active TB disease after having taken TB medicine in the past, residing in areas where drug-
resistant TB is common, being exposed to someone with drug-resistant TB disease and co-
infection with HIV (Marwar et al. 2009a). 
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1.6.2.1 Molecular mechanisms of drug-resistance 
 
 
Major advances in molecular biology tools and the availability of new information generated 
after deciphering the complete genome sequence of MTB has increased our knowledge of 
understanding of the mechanisms of resistance to the main anti-tuberculosis drugs. These have 
shown that specific gene mutations are associated with drug resistance (Almeida Da Silva & 
Palomino 2011) as shown in Table 1.2 
 
Gaining insight into how MTB develops drug resistance is essential to control the drug resistance 
epidemic. Mutations in the genome of MTB that can confer resistance to anti-TB drugs occur 
spontaneously with an estimated frequency of 3.5 x 10
-6
 for INH and 3.1 x 10
-8
 for RIF. Because 
the chromosomal loci responsible for resistance to various drugs are not linked, the risk of a 
double spontaneous mutation is extremely low: 9 x 10
-14
 for both INH and RIF. MDR-TB will 
thus occur mainly in circumstances where sequential drug resistance follows sustained treatment 
failure (Raja et al. 2010). 
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Table 1.2: Molecular mechanisms of drug resistance in Mycobacterium tuberculosis 
 
 
 
 
 
Drug (year of 
discovery) 
 
Isoniazid (1952) 
 
 
 
 
 
 
Rifampicin (1966) 
 
 
Pyrazinamide (1952) 
 
 
Ethambutol (1961) 
 
 
 
Streptomycin (1944) 
 
 
 
 
Amikacin/Kanamycin 
(1957) 
 
Capreomycin  
(1960) 
 
Fluoroquinolone (1963) 
 
 
 
Ethionamide  
(1956) 
 
 
PAS  
(1946) 
 
 
 
Gene(s) 
involved 
in 
resistance 
 
katG 
inhA 
ahpC 
kasA 
ndh 
 
 
ropB 
 
 
pncA 
 
 
embB 
 
 
 
rpsL 
rrs 
gidB 
 
 
rrs 
 
 
tlyA 
 
 
gyrA 
gyrB 
 
 
etaA/ethA 
inhA 
 
 
thyA 
 
 
 
 
 
 
Gene function 
 
Catalase-peroxidase 
Enoyl ACP reductase 
Alkyl hydroperoxide reductase 
β-ketoacyl-ACP Synthase 
NADH dehydrogenase 
 
 
β subunit of RNA polymerase 
 
 
Nicotinamidase/pyrazinamidase 
 
 
Arabinosyl transferase 
 
 
 
S12 ribosomal protein 
16S rRNA 
 rRNA methyltransferase (G527 in 
530 loop) 
 
16S rRNA 
 
 
2‟-O-methyltransferase 
 
 
DNA gyrase subunit A 
DNA gyrase subunit B 
 
 
Flavin monooxygenase 
Enoyl ACP reductase 
 
 
Thymidylate synthase 
 
 
 
 
 
 
    Role 
 
Pro-drug 
Conversion 
Drug target  
 
 
 
 
Drug target 
 
 
Pro-drug 
conversion 
 
Drug target 
 
 
 
Drug target 
Drug target 
Drug target 
 
 
Drug target 
 
 
Drug target 
 
 
Drug target 
Pro-drug 
conversion  
 
Drug target 
 
 
 
Drug 
activation? 
 
 
 
 
 
Mechanism of 
action 
 
Inhibition of 
Mycolic acid 
biosynthesis and 
other multiple 
effects 
 
 
Inhibition of 
RNA synthesis 
 
Depletion of 
membrane energy 
 
Inhibition of 
arabinogalactan 
synthesis 
 
Inhibition of 
protein synthesis 
 
 
 
Inhibition of 
protein synthesis 
 
Inhibition of 
protein synthesis 
 
Inhibition of 
DNA gyrase 
 
 
Inhibition of 
Mycolic acid 
synthesis 
 
Inhibition of folic 
acid and iron 
metabolism? 
Most 
frequently 
mutated 
codes 
associated 
with 
resistance 
 
katG 315 
 
 
 
 
 
 
rpoB 526,531 
 
 
 
 
 
 306 
 
 
 
43 & 88 
bp530&915 
 
 
 
bp1400 
 
 
 
 
 
90,91,94 
 
 
 
inhA21,94,44 
Sources: Almeida Da Silva & Palomino, 2011; Mathema et al. 2006. 
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1.7. Epidemiology of Mycobacterium tuberculosis 
 
1.7.1 TB epidemiology 
 
 
Even though the causative organism was discovered more than 100 years ago and that highly 
effective drugs and a vaccine are available, TB remains a worldwide public health problem 
(Marwar et al. 2009b).  The disease contributes considerably to illness and death around the 
world, exacting a heavy toll on the world‟s most vulnerable citizens (Ahmad, 2011a). 
 
It is estimated that one-third of the world‟s population has been infected with MTB (Pang et al., 
2012) resulting in more than eight million people contracting the disease annually. Of these, 
more than 25% die each year (Jagielski et al., 2010). TB continues to be one of the most 
challenging communicable diseases for developing countries where the situation is worse 
particularly in Sub-Saharan Africa (Amin, 2006). In 2003, an estimated nine million new cases 
of TB resulted in 1.7 million deaths. Twenty seven percent of these cases and 31% of these 
deaths arose in Africa, home to only 11% of the world‟s population (Corbett et al. 2006). 
According to the WHO, approximately 95% of the eight million new cases each year occur in 
middle-and low-income countries where 98% of TB death occur  with the highest prevalence and 
estimated annual risk of TB infection in sub-Saharan Africa and Southeast Asia (1.5% to 2.5% 
and 1% to 2% respectively) (WHO, 2008).  
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In 2011, the largest number of new TB cases occurred in Asia, with 60% of new cases globally. 
However, Sub-Saharan Africa carried the greatest proportion of new cases per population with 
over 260 cases per 100 000 population (WHO, 2012) (Figure 1.5). Almost 80% of TB cases 
among people living with HIV reside in Africa (WHO, 2012), indicating that the incidence of TB 
from sub-Saharan Africa is fuelled by the HIV epidemic (O‟Grady et al. 2011). Worldwide, 
3.7% of new cases and 20% of previously treated cases were estimated to have MDR-TB. India, 
China, the Russian Federation and South Africa have almost 60% of the world‟s cases of MDR-
TB (WHO, 2012).  
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Figure 1.5: A - Estimated of TB incidence rates, 2011 and B - Estimated HIV prevalence in new TB    
cases, 2011 Source: Global Tuberculosis Report, 2012. 
B 
A 
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1.7.2 Epidemiology of TB in South Africa 
 
 
South Africa remains the country with the greatest burden of HIV positive individuals and the 
second highest estimated TB incidence per capita worldwide (Houlihan et al. 2010). South 
Africa alone has 28% of the world‟s population of HIV and TB coinfected individuals (Louw et 
al. 2012). Approximately, 73% of the new TB cases in South Africa are co-infected with HIV 
which contributes to 84% of TB deaths in the country (Daftary & Padayatchi, 2012). The 
prevalence of HIV and TB is high throughout South Africa with the most escalating situation 
from the KwaZulu-Natal (KZN) province. Research conducted at Edendale Hospital in the KZN 
province, has observed that up to 50% of patients admitted to the hospital and 60% of women 
presenting for antenatal care are confirmed to be HIV positive (Dong et al. 2007). The province 
has the highest number of HIV-positive individuals (one million people) with even higher TB 
notification rates of 1094 cases per 100 000 population. The high HIV/TB prevalence figures 
together with TB drug-resistant (MDR-TB and XDR-TB) has gained national and international 
attention (Houlihan et al. 2010).  TB incidences in South Africa have kept rising since 2002 as 
presented in Figure 1.6. 
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Figure 1.6: Incidence of Tuberculosis (per 100 000 people) in South Africa 
Source: http://www.tradingeconomics.com/south-africa/incidence-of-tuberculosis-per-100-000-people-
wb-data.html  
 
 
 
1.8 Molecular Epidemiology of TB 
 
1.8.1 General overview   
 
The resurgence of TB in the world, but more importantly in developing countries has renewed 
interest in understanding the epidemiology and pathogenesis of the disease (Kehinde, 2012). The 
TB research community entered the genomic era in 1998 with the publication of the complete 
annotated genome of the MTB laboratory strain H37Rv. While previous methods, such as colony 
morphology, comparative growth rates, susceptibility to selected antibiotics, and phage typing, 
were useful, they did not provide sufficient discrimination of MTB strains, thus limiting their 
utility in TB epidemiology (Mathema et al. 2006a; Burgos & Pym, 2002). 
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The advancement of molecular techniques that allow identification and tracking of strains within 
MTBC has revolutionized TB research. The contribution of molecular epidemiological methods 
in the prevention and control of TB is made possible through their ability to differentiate 
between infecting strains, assessment of the overall diversity of circulating MTB strains, 
pinpointing differences by regions and subpopulations, and measurement of prevalence of 
endemic strains (Kehinde 2012). The clustered strains defined as two or more isolates from 
different patients but having a matching genotype may indicate recent transmission while non 
clustering isolates may indicate reactivation of TB disease. The gained information is vital in 
making TB policy (Rodwell et al. 2012). 
 
 
Over the past 15 years approximately 900 pertinent publications have substantiated the value of 
the genotyping approach for TB control. Several European countries have profited from 
nationwide prospective fingerprinting. After providing genotyping results to public health 
officials, these were able to document epidemiological links for substantially more TB patients. 
On a global scale, strain families and particular strains have been identified, characterized and 
traced in their spread (Prodinger, 2007). Unfortunately, only in the developed countries, where 
more resources are available, have the results been used to guide tuberculosis-control efforts 
(Barnes & Cave, 2003). 
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The essence of conducting molecular epidemiological studies has been demonstrated in other 
studies done elsewhere in the world. A study done in San Francisco, New York and Amsterdam, 
demonstrated that the rate of recent infection was much higher than the estimated 10% predicted 
by traditional epidemiological studies. In San Francisco, the study showed that almost one-third 
of new cases of TB were as a result of recent infection, while in New York and Amsterdam 
clustering was estimated to be 40% and 47%, respectively (Burgos & Pym, 2002). In another 
study conducted in Hong Kong it was shown that 88% of the isolates from patients with relapses 
matched those with the pre-treatment counterparts indicating a high frequency of occurrence of 
infections caused by endogenous reactivation of MTB (Narayanan, 2004). 
 
 
1.8.2 Genotyping Methodologies 
  
There are a wide variety of genotyping markers for MTB (Figure 1.8). However, only a few of 
these, namely Spacer oligonucleotide typing (Spoligotyping), Mycobacterial Interspersed 
Repetitive-Unit Variable Number Tandem Repeat (MIRU-VNTR), and  Insertion Sequence (IS) 
6110 Restriction Fragment Length Polymorphism (IS6110 RFLP), exhibit enough 
discrimination, have been internationally standardized and are currently the most commonly used 
in the globe (Hanekom et al. 2008). Spoligotyping and IS6110 RFLP are discussed in detail in 
chapters two and three respectively. 
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Figure 1.7: the genome of a virtual Mycobacterium tuberculosis complex isolate with the elements targeted by 
common genotyping methods indicated: (a) there are six copies of insertion element IS6110 in this genome, which 
will yield a strain-specific six-band RFLP pattern after hybridisation with an IS6110-specific probe. (b) The single 
DR locus harbours 36 bp direct repeats (boxes) and unique spacer sequences in between. Those are amplified by 
PCR at once and the strain-specific presence of 43 such spacers is tested in a next step by reversed line blotting. (c) 
Twelve VNTR loci (out of many more eligible for testing) are individually amplified by twelve sets of primers and 
the VNTR copy number is determined. The combination of the copy numbers from each locus is specific for a 
strain. VNTRs are between 40 and 100 bp in size, a size of 53 if often encountered MIRU-VNTRs.  
 
Adapted from: (Prodinger, 2007). 
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In summary, spoligotyping is a PCR – based technique targeting the well-conserved 36-bp direct 
repeat (DR) regions in MTB which are interspersed with nonrepetitive spacer sequences of 34 to 
41 bp in length. Its detection of polymorphism in the direct repeat region is based on identifying 
the presence or absence of 43 spacer DNA sequences between the variable direct repeats (VDRs) 
(Asho et al. 2008; Boer et al. 2004). The polymorphisms detected by spoligotyping are used to 
identify some members (i.e. M. bovis) of MTBC and distinguish MTB into distinct families and 
sub families that are quiet useful for identifying the source and spread of TB, TB control, and 
examining host-pathogen relationships. The major families of MTB include Beijing, CAS, T, 
LAM, X, H, S, EAI and MANU. These major families are further divided into sub families. 
Some of the sub families are; typical and atypical for the Beijing family, CAS-Kili, CAS-Delhi 
for the CAS family, T1, T2, T3 etc for the T family, LAM1, LAM2, LAM3, LAM4 etc for the 
LAM family, X1, X2 etc for the X family, H1, H2, H3 etc for the H family and EAI1 – SOM for 
the EAI family. These major families and sub families have been extensively studied through 
molecular epidemiological studies and have assisted to shed light on TB dynamics (Ozcaglar et 
al. 2011; Demay et al. 2012). 
 
The IS6110 RFLP technique is currently considered the gold-standard method for MTB typing. 
It is based on the occurrence of number and location of the IS6110 element which is unique to 
MTB. Different strains carry different copy numbers of the IS6110 elements and this 
polymorphism is highly discriminatory and reproducible to genotype the isolates (Asho et al. 
2008; Van Embden et al. 1993; Yang et al. 1995). 
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MIRU-VNTR is one of the PCR based methods which is used to genotype MTB                
(Alonso-Rodríguez et al. 2008). This technique has been introduced recently, and is currently the 
most used method, based on determining the length variation at 12 independent minisatellite-like 
loci scattered throughout the MTB genome (Sun et al. 2004; Allix-Béguec et al. 2008). The ease 
with which this PCR-based technique can be performed, its adaptability to high-throughput 
automation, and the digital format of MIRU-VNTR patterns make this method suitable for the 
global study of the molecular epidemiology of MTB. In addition, MIRU-VNTR typing has a 
high discriminatory power for MTB strains with a low copy number of IS6110 or that are devoid 
of IS6110 (Y. Sun et al. 2004). 
 
The evaluation of MIRU-VNTR in several genotypic studies has shown that the discriminatory 
power is equivalent to that of IS6110 RFLP and is considered to be an alternative to RFLP for 
epidemiology purposes. However, other authors have found limitations in its discriminatory 
power and incomplete correlation with the IS6110 RFLP analysis, indicating that MIRU analysis 
should be combined with an additional genotyping method (Alonso-Rodríguez et al. 2008). 
 
In order to improve the standard of the most recent MIRU-VNTR technique, a standardized 
MIRU-VNTR format composed of 24 loci with a high discriminatory power has been proposed. 
This is on the basis of analyzing the clonal stability and evolutionary rates of MIRU-VNTR 
marker in primary genetic lineages of tubercle bacilli from around the world. Of the 24 loci, 15 
are defined as composing a discriminatory subset based on a higher variability within the 
different clonal complex as studied (Allix-Béguec et al. 2008).  
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1.8.3 Molecular Epidemiology of TB in South Africa 
 
 
 
The management of TB, especially MDR-TB and XDR-TB depends on an understanding of the 
population structure, as well as the prevalence and spread of TB strains driving the epidemic 
(Said et al. 2012a). This is mainly achieved through molecular epidemiological studies, which 
generate data regarding the strains that are circulating in a particular area. Unfortunately, despite 
South Africa ranking third on the world‟s 22 high burden TB countries (Said et al. 2012b), there 
is only limited data regarding the locally circulating strains. Based on the literature search, the 
majority of the molecular epidemiological studies that have been done in the country are on 
strains from the Western Cape Province (WCP), done by the Centre for Molecular and Cellular 
Biology at the University of Stellenbosch. As a result, the available data does not represent all 
the regions of South Africa. Of the few studies done in WCP and in some other parts of South 
Africa, the findings demonstrate the usefulness of molecular epidemiology.  
 
To date, there is only one national molecular epidemiological study, which has been conducted. 
A national molecular epidemiological study (from eight provinces; Eastern Cape, Free State, 
Gauteng, KwaZulu – Natal, Northern Province, Mpumalanga, North West and Western Cape) on 
MTB isolates which were obtained during a national survey in 2001 – 2002, demonstrated a high 
diversity in the MTB genotypes in the country as 10 different lineages were found (Stavrum et 
al. 2009a). The most predominant lineages were found to be the T family ST53 (25.8%), 
followed by Beijing (10.3%). All the lineages were observed in MDR-TB except MANU2 and 
H37Rv. Despite the survey suggesting that there is no specific lineage that contributes to the 
spread of TB disease in the country, the sample size was too small (n=252) to give a true 
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indication on the TB dynamics in the different provinces. For example, Gauteng province with a 
population of more than 11 million was only represented with 35 isolates making 13% of the 
study (Stavrum et al. 2009a). Therefore, more information is needed in order to better understand 
the distribution of strains circulating within specific regions in the country. 
 
Of the few molecular studies done in the country, some have demonstrated that TB may be due 
to specific lineages. The MTB genotype LAM3 (F11), characterized by a lack of spoligotype 
spacers 9 to 11, 21 to 24, and 33 to 36, and appear to be a unique marker of this strain family, 
represented the largest proportion of all isolates from TB patients in one of the studies from 
WCP (Streicher et al 2004). The authors suggested it may be at least as successful as the Beijing 
genotype in contributing to the TB problem in WCP of South Africa (Victor et al. 2004). The 
predominance of one family was also shown in a different study in the same province where the 
sub-group of Beijing family, termed R220 based on IS6110 RFLP banding pattern, was 
overrepresented among drug-resistant isolates, giving an indication that the TB drug-resistance in 
the area during that time was largely caused by one lineage of MTB (Johnson et al. 2010). 
 
Furthermore, studies done in KZN have also demonstrated that the incidences of drug-resistant 
TB are mostly due to clonality. It has been shown that LAM4 (SIT 60) is the most predominant 
genotype circulating in the area.  In an XDR-TB study, of the 86 XDR-TB isolates, 92% (79) 
belonged to the genotype LAM 4 SIT 60 and this was found to be due to clonality after DNA 
sequencing of the 10 resistance determining regions of these isolates demonstrated identical 
mutations across all genes tested (Gandhi et al. 2013). In another study, analysis of 102 MDR-
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TB isolates in 2005 from one district in KZN showed that 60 (59%) of these isolates belonged to 
the F15/LAM4/KZN (Pillay & Sturm, 2007). 
 
Incidences of TB are very high in South African mines where close monitoring of spread of the 
disease is required (Hanifa et al. 2009). A molecular study conducted from a certain mine in 
South Africa, observed clustering of isolates to be more frequent among case-patients with 
MDR-TB than mono-resistant strains. Again, comparison of clustering rate among pre-XDR-TB 
and XDR-TB isolates showed that highly resistant strains were more likely to belong to a cluster 
than those with less resistance. It was also noted that 59% of clustered case-patients had a 
documented previous episode of TB, which suggested re-infection with a circulating strain. This 
suggested that the current TB control program was largely able to prevent the acquisition of 
drug-resistance to at least the first-line drugs but could not prevent the transmission of pre-
existing MDR-TB in this highly vulnerable population (Victor et al. 2004). 
 
Demonstration of mode of transmission through molecular techniques has been achieved in some 
studies. A recent study showed that Beijing strains among XDR-TB were evolving and were 
spreading adaptively rather than by clonal expansion while MDR-TB was being transmitted 
clonally. This clonal transmission of MDR was demonstrated by the observation that isolates in 
the Beijing R220 cluster shared the same c-15t inhA promoter mutation, and isolates in the 
Beijing R86 cluster shared the same katG S315T mutation. Unlike in MDR-TB, in XDR-TB the 
mutations were not clonally related (Ioerger et al. 2010). 
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There have been limited molecular studies done in the Gauteng province of South Africa. An 
XDR-TB study done in Gauteng Province but on isolates from four different provinces 
(Limpopo, Gauteng, North West, and Northern Cape) to determine whether XDR-TB was 
primarily transmitted or acquired, demonstrated high diversity of XDR-TB strains with Beijing 
genotype family being the largest in the study contributing 34% of all the isolates. The analysis 
of the data further revealed that majority of XDR-TB cases was due to drug acquisition rather 
than transmission. This was supported by the high default rate (30%) from TB treatment for the 
MDR-TB patients (Mlambo et al. 2008). The Beijing family, also dominated (16%) in an 
epidemiological study of spread of multidrug-resistant tuberculosis in Johannesburg (Marais et 
al. 2013). In a similar study conducted in the same province of Gauteng in Pretoria, the Beijing 
family was the most predominant seconded by the T1 family (Hove et al. 2012).  
 
 
A community based study done in the Western Cape Province of South Africa identified an 
outbreak of drug-resistant TB involving strains that belong to a newly describing genotype, the 
DRF150. This clone represented almost half of the cases of drug-resistant TB identified in the 
George sub-district during the study period. This shows the risk of widespread transmission of 
drug-resistant strains that are not of the Beijing/W lineage, and suggests that circulation of 
further currently unrecognized drug-resistant strains may contribute to the South African drug-
resistant TB epidemic (Victor et al. 2007).   
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Studies have shown that the global TB epidemiology is caused by different genotypes, and these 
genotypes occur at frequencies that differ between district, cities, countries, and continents. In 
South Africa, the population structure of MTB strains differs among the provinces (Said et al. 
2012b). However, little information is available from some parts of South Africa. Johannesburg 
is the most densely inhabited industrialized city in South Africa as well as the financial hub of 
Africa yet very little is known about the circulating strains types, compared to the vast amount of 
data forthcoming on the genotypic diversity of strains from the WCP. It is possible that the types 
of MTB strains/families in this area are not the same as those identified in the WCP. Though 
patient management may not vary according to strain type, the ability to differentiate genotype 
families between geographical locations may have an impact on clinical and epidemiological 
future plans for a particular location (Schürch & van Soolingen 2012). 
 
 
1.9. Aim and objectives of the study 
 
1.9.1 Aim 
 
 
This study aimed firstly to determine the genetic diversity of drug susceptible and drug resistant 
MTB strains isolated from patients with TB residing in the Johannesburg area; secondly to 
compare the genetic diversity of these strains to national as well as international databanks and 
finally to determine whether there is a predominant clone that is circulating in the area.  
 
 
 
 
38 
 
 
 
 
 
1.9.2 Study Objectives 
 
The study objectives are summarized as follow:  
 
1. To collect and categorize the isolates according to the drug susceptibility pattern. 
2. To detect and type MTB and determine groups of related strains through spoligotyping. 
3. To characterize groups of related strains by IS6110 RFLP. 
4. To compare the genotypic data to national and international databanks. 
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Chapter two: Spoligotyping of Mycobacterium tuberculosis strains 
 
2.1 Introduction 
 
TB has gained critical attention (Guernier et al. 2008) being one of the deadly disease for 
decades and remains a problem in developing countries particularly in Sub-Saharan Africa which 
is fuelled by HIV epidemic (Pang et al. 2012). The TB problem in South Africa has further been 
exacerbated by the emergence of MDR-TB and XDR-TB which is believed to be due to either 
non-adherence to drug regimens or the use of inappropriate drug regimens (Stavrum et al. 
2009a).  
 
A clear understanding of the transmission of the disease and the establishment of infection 
contributes to the development of effective prevention and control measures for TB. The use of 
molecular techniques to characterize Mycobacterium strains, particularly the MTB strains and 
the concomitant accumulation of epidemiological data has increased the possibility to trace 
transmission routes of MTB outbreaks (Guernier et al. 2008). By providing insight into the 
transmission dynamics, source and spread of MTB, molecular studies have enhanced our 
knowledge of TB epidemiology (Wang et al. 2012; Pang et al. 2012). Through a genotypic study, 
patients with identical MTB genotypes can be identified and are designated as cluster cases 
which may be indicative of recent transmission (Guernier et al. 2008). This estimation of recent 
transmission through molecular epidemiologic methods is regarded as an important indicator for 
surveillance and TB control programs (Wang et al. 2012). Through molecular studies, it is 
possible to establish the existence and spread of particular strain families in defined geographic 
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regions (Wang et al. 2012), which may significantly increase our capacity to monitor the 
transmission and to prevent secondary cases (Blanca et al. 2010).  
 
Spoligotyping is a reliable and informative technology for characterizing the genetic structure of 
MTB populations (Pang et al. 2012). The method is suitable for large studies on phylogeny and 
identification of genotype families (Abadía et al. 2009), and has gained widespread acceptance 
because it is a simple, rapid, and robust method. Results can be expressed in a simple digital 
format that is easier to compare and store, in comparison with those of other available 
techniques. Thus it has been extensively applied, alone or in conjunction with other techniques 
(Bezos et al. 2004). 
 
 
2.1.1 The General overview of Spoligotyping 
 
Spoligotyping is a PCR – based technique first described in the mid 1990s and is based on DNA 
polymorphisms at a single chromosomal locus characterized by the presence of a high number of 
conserved direct repeats. This so-called Direct Repeat (DR) region consists of directly repeated 
sequences that are interspersed by DNA spacers (Figure 2.1). When the direct repeat regions of 
several isolates were compared it was noted that the order of spacers was nearly the same in all 
isolates, but that many deletions and/or insertions occurred in different strains. Because 
spoligotyping is a PCR driven technique, only small amounts of DNA are required for analysis, 
so the method is particularly suitable for the analysis of slowly growing Mycobacteria. It also 
permits the comparison of isolates which are not suited for re-culture after prolonged storage 
(Boer et al. 2004).  
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      Key 
 
    Figure 2.1: Annealing of the primers to the DRs and PCR products. Adapted from Honisch et al. 2010 
 
 
 
PCR products with biotin 
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The spacer nucleotides between the direct repeats can be amplified simultaneously using a single 
set of primers that target the DR sequences. The presence or absence of spacers in a given strain 
is determined by hybridization with a set of 43 oligonucleotides derived from spacer sequences 
of MTB H37Rv. These (oligonucleotide) spacers derived from the known spacers in the DR 
cluster are covalently linked to an activated membrane in parallel lines. PCR products are 
hybridized perpendicular to the oligo lines. After hybridization the membrane is incubated in 
streptavidin peroxidase, which binds to the biotin label on the PCR products. Detection of the 
hybridization signals are optimized by the enhanced chemiluminescence (ECL). The peroxidase 
present on the streptavidin catalyzes a reaction resulting in the emission of light, which can be 
detected by autoradiography of the membrane. The presence of the spacers is visualized on film 
as black squares after incubation with streptavidin-peroxidase and ECL-detection (Narayanan, 
2004; Bezos et al. 2004). 
 
Although the overall discriminatory power of spoligotyping is lower than that of IS6110 RFLP 
typing that is still considered as the gold standard for typing, it has the specific advantage of 
higher discrimination of strains with low copy numbers of IS6110 (Figure 2.2) (Narayanan, 
2004). Other advantages of spoligotyping over IS6110 RFLP method is that spoligotyping only 
requires a small amount of sample DNA and this can be obtained from liquid culture or direct 
form the specimen i.e. sputum. Furthermore spoligotyping data, which is represented in absolute 
terms, can be readily shared among laboratories thereby enabling the creation of a large 
international database (SpolDB) (Warren et al. 2002; Millet et al. 2009; Kehinde, 2012). This 
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development allows investigators to survey strain diversity and uncover global strain families 
such as the Beijing and Latin American Mediterranean (LAM) families. The method has been 
very successful in providing a tool for the rapid acquisition of MTB genotyping information and 
for the establishment of a global picture of MTB diversity. It is highly reproducible and has been 
developed into a high-throughput assay for large molecular epidemiology surveys (Kehinde, 
2012; Millet et al. 2009). The strengths of this method include its low cost, digital data results 
and good correlation of results with other genetic markers. It further offers a fair level of overall 
differentiation of MTB strains, has high-throughput capacity, and is able to provide species 
information within the MTBC (Kehinde, 2012; Warren et al. 2002). 
 
 
 
Figure 2.2:  structure of the Direct Repeat locus in the genome of MTB H37Rv and M.bovis BCG P3. 
The green rectangles depict the 36 bp Direct Repeat region while the strait black lines in between Direct 
Repeats, represents the unique spacers. Adapted from Boer et al. 2004 
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2.2 The aim of the study 
 
 
The purpose of this study was to genotype the MTB isolates through spoligotyping and to 
determine the predominant strain types circulating in the Johannesburg area. Furthermore the 
aim was to identify whether the TB incidences are due to clonality or due to different strain 
types. In addition we aimed to determine if there are certain strain types were more associated 
with resistance than others. Lastly, we aimed to characterize a subset of isolates through IS6110 
RFLP in order to setup the RFLP procedure in the department as well as to correlate the results 
for the two methods mainly for the clustered MTB isolates.  
 
2.3 Materials and Methods 
 
2.3.1 Study design 
 
 
This was a retrospective and descriptive study of MTB isolates that were one year or two years 
(2009 and 2010) old. These isolates were stored in the routine culture laboratory after routine 
testing. Thus drug susceptibility results were already available from routine culture and drug 
susceptibility testing of TB suspects within the National Department of Health TB Control 
programme, in Gauteng.  
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2.3.2 Ethics approval  
 
 
The study received ethical approval from the University of Witwatersrand Human Research 
Ethics Committee. The study clearance certificate number is M111113. 
 
 
2.3.3 Sample collection procedure and demographics 
 
 
The Mycobacterium tuberculosis complex (MTBC) isolates were collected from the National 
Health Laboratory Services (NHLS) Mycobacteriology Referral Laboratory in Braamfontein, 
Johannesburg. This laboratory serves as the routine diagnostic mycobacterial culture and drug 
susceptibility testing laboratory for Gauteng, with the majority (about 60%) of specimens 
primarily submitted from the Chris Hani Baragwanath, Charlotte Maxeke Johannesburg 
Academic, Helen Joseph hospital (all tertiary academic hospital linked to the University of the 
Witwatersrand) and Sizwe drug resistant TB hospital (where all newly diagnosed MDR-TB 
patients are admitted in the Gauteng province. It also provides culture services to about 100 TB 
clinics in Gauteng province, as well as to prisons. The laboratory also receives specimens from 
TB culture laboratories in other provinces of South Africa such as Limpopo, Mpumalanga, and 
from outside the country or second-line drug susceptibility testing. It performs drug 
susceptibility testing for first line (Rifampicin, Isoniazid, Streptomycin, Ethambutol, and 
Pyrazinamide) as well as second line (Ethionamide, Kanamycin and Ofloxacin). The laboratory 
is accredited with SANAS (South African National Accreditation System) and subscribes to 
External Quality Assurance (EQA) programmes (e.g. College of American Pathologist CAP) 
thrice a year. 
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2.3.3.1 Specimen origin 
 
 
The study tested MTB isolates from specimens that originated from TB suspects from within the 
seven regions of Johannesburg (Figure 2.3). This city is the most densely populated city in South 
Africa, and with a population of 3,888,180 is the provincial capital of Gauteng province and the 
financial hub of South Africa (Community Survey report; 2007).  
 
2.3.4.2 Specimen identification and selection 
 
The MTB isolates collected from the NHLS Mycobacteriology referral laboratory were 
identified through searching the laboratory information system (LIS). The isolates were 
consecutively selected so that no bias in selection process occurred.  Based on the demographic 
data, each specimen obtained was categorized according to its geographical region of origin 
(patient residential address). Only specimens originating from the seven regions of Johannesburg 
(Figure 2.3) were included in this study. These included specimens from males and females, all 
age groups and all specimen types. The ethnicity or nationality was not considered, as we were 
blind to the information. Isolates were excluded if neither the physical address nor the clinic 
name was indicated as it could then not be ascertained if the specimen originated from one of the 
seven mentioned regions. All patient duplicate samples were removed. The collection of isolates 
from patients from all the seven regions of Johannesburg was to ensure that the study sample was 
well represented, even though analysis of results will not focus on the individual regions. The 
number of isolates tested from each region of Johannesburg is indicated in Figure 2.3. 
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Figure 2.3: Map illustrating the seven administrative regions of Johannesburg (A-G) where of MTB 
isolates originated from. Total numbers of isolates are shown as per region. Map taken from 
www.joburg.org 
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Isolates were tested from tubes of positive Mycobacterial Growth Indicator Tube (MGIT) culture 
(BD BioSciences, Sparks, MD, USA). Each MGIT tube had a unique laboratory identification 
number that is linked to demographic data such as date of birth, gender and physical address. 
Each specimen was re-assigned a unique study number (SN) and hence delinked from patient 
identifiers, once regions were documented. No patient information was collected. By the time of 
selection, the drug susceptibility testing (DST) information of each isolate was available from the 
LIS. Based on this information, isolates were grouped into 5 drug susceptibility result categories 
as shown in Table 2.1. 
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Table 2.1: Description of drug susceptibility categories 
 
 
 
Drug susceptibility category 
 
 
Definition 
 
 
 
Susceptible MTBC 
 
 
MTBC with no resistance to RIF and INH 
 
 
 
Mono – resistant MTBC 
 
 
 
MTBC resistant to RIF or INH but not to both 
 
 
 
Multidrug – resistant MTBC 
(MDR-TB) 
 
 
MTBC resistant to at least both of RIF and INH (but not 
ofloxacin or to one of the three injectable second line drugs 
[AMK, KM or CPM]). 
 
 
 
 
Pre – XDR MTBC 
 
 
MDR-MTBC that is also resistant to one of the three second 
line injectable drugs or to ofloxacin. 
 
 
 
 
XDR MTBC 
 
 
MDR-MTBC that is also resistant to one of the three second 
line injectable as well as resistant to ofloxacin. 
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The total number of isolates collected per drug susceptibility category is shown in figure 2.4. 
 
 
 
 
Figure 2.4: Number of samples collected per drug susceptibility category. 
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Resistance of MDR isolates in other MTB drugs such as STR, EMB, ETHIO and PZA, differed 
considerably as shown in figure 2.5. 
 
 
 
 
 
 
 
Figure 2.5: Presents 108 isolates and six TB drugs showing the extent of drug resistant for 
MDR-TB isolates included in this study. 
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2.4 Spoligotyping 
 
 
Spoligotyping was performed out using a commercially available kit (Isogen Bioscience BV, 
Maarssen, Netherlands) according to the manufacturer‟s instructions. As mentioned, 
spoligotyping targets the direct repeats (DRs) present in multiple copies in the genomic DR locus 
of MTB complex bacteria. The well-conserved 36 bp DRs are interspersed with nonrepetitive 
spacer sequences of 34 to 41 bp in length. The variation of these spacer sequences among strains 
of the MT complex allows for the genotyping of the Mycobacterium tuberculosis complex. 
Spoligotyping was performed using the primers DRa (5‟GGTTTTGGGTCTGACGAC3‟) and 
DRb (5‟CCGAGAGGGGACGGAAAC3‟) as originally described by Kamerbeek et al 1997. The 
method involves three main steps; (A) in vitro amplification of spacer DNA by PCR, (B) 
Hybridization of the PCR product and detection, and (C) Regeneration of the membrane for next 
Hybridization. 
 
2.4.1 Specimen processing for spoligotyping 
 
 
Using aerosol resistant tips to avoid contamination, 400ụl of culture from each MGIT was 
transferred to a screw-cap tube and incubated at 80˚C for 30 minutes using the Accu Blocktm 
Digital Dry Bath (Lab-Net) in order to lyse the bacterial cells. The screw-cap tubes were used to 
prevent aerosol formation during the heat killing process. The process of heat killing the 
mycobacterial cells was done in a Biosafety level III laboratory. The heat killed isolates were 
stored frozen in microcentrifuge tubes at -20˚C until the time of use. 
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2.4.2 Preparation of the PCR Mixture 
 
 
DNA amplification was performed as previously described (Kamerbeek et al. 1997) using DRb 
(5‟-CCGAGAGGGGACGGAAAC-3‟) and primer DRa (5‟-GGTTTTGGGTCTGACGAC-3‟). 
The PCR reaction mixture used in all spoligotyping applications contained 1X Master Mix: 
0.05U/µl Taq DNA polymerase, 2mM MgCl2, 0.2mM each of the deoxynucleotide triphosphates 
(dNTPs) (Fermentas Life Science, Glen Burnie, MD, USA), 2µM of the primer pair (DRa, DRb) 
and, 1µg DNA made up to the final volume of 25µl with sterile water. Amplification was 
performed using an iCycler Thermocycler (Bio-rad Hercules, CA, USA) starting with a 
denaturing step for 3mins at 96˚C, followed by 30 cycles of 1min at 96˚C, 1min at 55˚C and 
30sec at 72˚C. This was followed by a final extension step of 72˚C for 10mins. DNA from MTB 
strain H37Rv and M.bovis BCG were used as positive controls and sterile water was used as a 
negative control in each run. 
 
2.4.3 Hybridization 
 
 
After the PCR was completed, 20µl of the PCR product was added to 150µl 2 X SSPE/0.1%SDS 
in a microcentrifuge tube. The mixture was placed at 99˚C (Dry Block Heater HB2 hägar 
designs) for 10 mins in order to denature the diluted PCR product. Immediately after denaturing, 
the tube was placed on ice until the process of washing the membrane and assembling of the 
miniblotter was complete. The spoligotyping membrane (Isogen, Bioscience BV, Utrecht, The 
Netherlands) was washed in 2 X SSPE/0.1% SDS for 5 minutes in a hybridization oven (MWG-
Biotech AG, Ebersberg, Germany) at 57˚C. The membrane was then placed on a support cushion 
in a miniblotter (Isogenic, Bioscience BV, Utrecht, Netherlands). 
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After preparation of the PCR product and assembly of the miniblotter/membrane, any excess 
buffer remaining after pre-treating the membrane was aspirated. The slots were then slowly filled 
with the diluted denatured PCR product, with careful attention to avoid forming air bubbles in 
the slots. The first and last slots on the miniblotter were loaded with 2 X SSPE/0.1% SDS buffer, 
leaving the remaining lanes for samples and controls. After loading, the miniblotter/membrane 
was placed in a hybridization oven (MWG-Biotech AG, Ebersberg, Germany) for 60 minutes at 
57˚C without shaking to avoid cross flow as this could lead to contamination.  
 
2.4.4 Detection 
 
 
PCR products were removed by aspiration from the miniblotter slots after hybridization was 
complete. The membrane was washed twice in 2 X SSPE/0.5 SDS for 7 minutes at 57˚C after 
which it was placed in a rolling bottle (GATC TUBE detection system-Germany). Thirty 
millilitres of 2 X SSPE/0.5 SDS (42˚C) was added with 7.5µl streptavidin peroxidase conjugate 
(500U/ml) in a 50 ml tube and gently mixed. The mixture was poured onto the membrane in a 
rolling bottle and incubated for 60 minutes at 42˚C. After incubation, the membrane was washed 
twice with 2 X SSPE/0.5% SDS for 10mins at 42˚C, followed by rinsing with 2 X SSPE for 
5mins at room temperature. The detection step was achieved with the use of ECL detection 
liquid (Amersham Biosciences, Buckinghamshire, UK). The membrane was incubated in 10ml 
detection mixture (5ml of ECL detection solution 1 and 5ml ECL detection solution 2) for 90 
seconds then transferred to a clear plastic bag. After heat-sealing, the bag was transferred into a 
25 x 30 cm film cassette (Amersham Biosciences, Buckinghamshire, UK). The film was exposed 
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to the membrane for periods ranging 20 seconds to 1 minute in a dark room at the Radiology 
Department at the Charlotte Maxeke Johannesburg Academic Hospital, and developed using a 
Kodak RPX-OXMAT Processor (Eastman Kodak Company, New York, USA). 
 
 
 
2.4.5 Stripping the Membrane 
 
 
Removal of the PCR products from the membrane (stripping) was done by washing the 
membrane twice in 1% SDS at 80°C for 40 minutes. The membrane was further washed in 
20mM EDTA, pH 8, for 15 minutes at room temperature, and then sealed in a plastic bag 
containing a small amount of 20mM EDTA, pH 8, to keep the membrane moistened and stored 
at 4°C until further use. 
 
2.4.6 Interpretation of the results 
 
 
Results from the spoligotype membrane autoradiographs were analyzed by recording the 
presence or absence of signals at the sites of DNA/DNA hybridizations. The presence of spacers 
was represented on film as black squares after incubation with streptavidine-peroxidase and ECL 
detection. Results were entered in a binary format into excel spreadsheets and compared with the 
published spoligotyping database SpolDB4 of the Pasteur Institute, Guadeloupe (Brudey et al. 
2006) as well as with the updated version SITVIT 2 from the Pasteur Institute in Guadeloupe.  
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2.4.6.1 Estimation of recent transmission 
 
 
The estimation of transmission was done according to the n-1 method: RTIn-1 = (nc-c)/n, where n 
is the total number of cases in the sample, nc is the total number of cases in cluster and c is the 
number of genotypes represented by at least two cases. The concept is that a more genetically 
homogenous data set would represent a more severe extent of disease transmission i.e. an 
outbreak (Guernier et al. 2008). 
 
 
2.5 Statistical analysis 
 
 
Pearson‟s Chi-square test was used to determine statistical association between predominant 
spoligotyping families and drug-resistance. Statistical Package for Social Science Software 
(SPSS, USA) was used for analysis. P values <0.05 was considered significant. 
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2.6 Spoligotyping results 
 
 
The study included a total of 500 MTC isolates as shown in Figure 2.6. 
 
 
 
Figure 2.6: Total number of MTC isolates analyzed from each sensitivity category 
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Spoligotyping of the 500 isolates generated 62 shared types i.e. an identical pattern shared by 
two or more patients worldwide (within this study, or matching another strain in the SITVIT2 
database). Ninety two percent of our sample matched the pre-existing shared types. Thirty one 
[467/500 (93%)] shared types were clustered (2 to 135 per cluster). Detailed spoligotyping 
results are summarized in Table 2.2. Of the thirty one clustered shared types, eight were 
predominant (clustering from 16 to 135 per cluster) constituting 68% (340/500) of all (500) 
typed isolates and 73% (340/467) of all shared types found.  
 
 
The other 20 shared types clustered 2 to 8 representing 17% (87/500) while 31 (6.2%) shared 
types (non clusters) represented the single isolate (Table not shown). Forty two (8.4%) isolates 
were found to be undefined (absent in the SpolDB4.0 data base) and were termed orphans (Table 
2.5). 
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Figure 2.7: Presence (black blocks) and absence (empty spaces) of spacers in each isolate displayed on 
the X – ray film. 
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Table 2.2:    Description of 59 (SIT) shared types  
 
 
SITn 
 
      Clade 
 
Binary (Spoligotype) Description 
Total 
strains  
 
% in 
this 
study 
     
 1    Beijing 
   
 
 
 
 
 
 
135 
 
27
% 
 
190    Beijing    1 
 
0.2 
 
255    Beijing    1 
 
0.2 
 
53       T1 
 
 
 38 
 
8.2 
 
766       T1    1 
 
0.2 
 
771       T1    3 
 
0.6 
 
136       T1    1 
 
0.2 
 
1597       T1    3 
 
0.6 
 
719       T1    6 
 
1.2 
 
358       T1    1 
 
0.2 
244       T1 
 
 
 
   6 
 
1.2 
 
154       T1     1 
 
0.2 
 
1210       T1     1 
 
0.2 
 
373       T1     1 
 
0.2 
 
191       T1     1 
 
0.2 
 
649       T1 
 
 
    4 
 
0.8 
 
613       T1     1 
 
0.2 
 
52       T2     5 
 
  1 
 
37       T3     3 
 
0.6 
 
73    T2-T3     3 
 
0.6 
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c c c c c c c c c c c c c c c c c c c c c c c c c c c c c c c c c c g g g g g c g g g
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g g g g g g g g g g g g c g g g g g g g g g g g g g g g g g g g c c c c g g g g g g g
g g g g g g g g g g g g c g g g g g g g g g g g g g g g g g g g c c c c g g g c g g g
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Table 2.2: continues. 
     
 
SITn 
 
      Clade 
 
Binary (Spoligotype) Description 
Total 
strains  
 
% in 
this 
study 
 
33    LAM 3 
 
 
  30 
 
  6 
1295 
   
LAM 3 
 
     1 
 
 
0.2 
 
60    LAM4 
 
 
   41 
 
8.2 
 
811    LAM4 
 
 
     6 
 
1.2 
 
1710    LAM4      1 
 
0.2 
 
59 LAM11_ZWE      8 
 
1.6 
 
815 
LAM11_ZW
E 
 
 
     3 
 
0.6 
 
813 
LAM11_ZW
E      1 
 
0.2 
 
1607 
LAM11_ZW
E      1 
 
0.2 
 
42    LAM9      7 
 
1.4 
 
207    LAM9      1 
 
0.2 
 
95    LAM6      1 
 
0.2 
 
20    LAM1       4 
 
0.8 
1092 
CAS1_DEL
HI 
 
 
     1 
 
0.2 
26 
CAS1_DEL
HI 
 
     2 
 
0.4 
    21 
CAS1_KILL
I 
 
     6 
 
1.2 
 
334 
CAS1_KILL
I      1 
 
0.2 
 
776 CAS      2 
 
0.4 
 
34       S 
 
 
    42 
 
8.4 
 
1296        S      1 
 
0.2 
71        S 
 
 
     6 
 
1.2 
g g g g g g g g c c c g g g g g g g g g c c c c g g g g g g g g c c c c g g g g g g g
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g g g g g g g g g g g g g g g g g g g g c c c c g g c c c c g g c c c c g g g g g g g
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Table 2.2: continues. 
 
        
SITn Clade                                 Binary (Spoligotype) Description Total 
strains  
 
% in 
this 
study 
 
88 
       
 S 
 
 
    
    1 
 
0.2 
 
48 
 
EAI1_SOM 
 
 
 
     
    17 
 
  3 
 
806 
 
EAI1_SOM 
 
 
 
 
     
    1 
 
0.2 
 
625 
     
 EAI5 
 
 
      
    2 
 
0.4 
 
129 
     
 EAI5 
 
 
 
 
    2 
 
0.4 
 
4 
LAM3 & 
S/convergent 
 
 
 
    3 
 
0.6 
 
92 
        
X3 
 
 
 
    16 
 
3 
     
62 
 
H1 
 
 
       
    1 
 
0.2 
 
49 
        
H3 
 
 
 
  
    1 
 
0.2 
 
50 
        
H3 
 
 
 
 
21 
 
4.2 
 
1533 
        
H3 
 
 
       
    1 
 
0.2 
 
36 
        
H3_T3 
 
 
       
    1 
 
0.2 
 
54 
   
MANU2 
 
 
       
    1 
 
0.2 
 
451 
 
H37Rv 
 
 
       
    1 
 
0.2 
 
784 
   
T2-S 
 
 
  
    1 
 
0.2 
 
29 
 
Unknown  
 
 
       
    1 
 
0.2 
 
32 
 
Unknown 
 
 
       
    1 
 
0.2 
 
563 
 
Unknown 
 
 
      
     1 
 
0.2 
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g g g g g g g g g g g g g g c c g g g g g g g g g g g g g g c g c c c c g g g g g g g
g g g g g g g g g g g g c g g g g g g g g g g g g g g g g g c g c c c c g g g g g g g
g g g g g g g g g g g g g g g g g g g g g g g g g g g g g g g g c c g g g g g g g g g
g g g g g g g g g g g g g g g g g g g c c g g g g g g g g g g g c c c c g g g g g g g
g g g g g g g g c c g g g g g g g g g g g g g g g g g g g g g g c c c c g g g c g g g
g g g g g c c c c c c c c c c c c g g c c c c c c c c c c c c c c c c c c c g g g g g
g g g g g g g g c c c c c c c c c c c c c c c c c c c c c c c c c c c c c c g g g g g
g g g g g g g g g g g g c g g g g g g g g g g g c c c c c c c c c c c c c c c g g g g
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Eight spoligotyping families formed the predominant group of the study. Of these eight families, 
Beijing SIT1 was the most predominant at 27% seconded by S SIT 34 at 8.4%. The LAM4 SIT 
60 and T1 SIT 53 both represented 8.2%, LAM3 SIT 33 represented 6%, H3 SIT 50 represented 
4.2% while EAI1- SOM SIT 48 and X3 SIT 92 both represented 3%. The Beijing family 
dominated in all susceptibility patterns while LAM 4 SIT 60 was well represented in XDR – TB 
(Figure 2.9). The H3 and EAI1-SOM were almost equally distributed in all sensitivity patterns 
while LAM 3 and T1 families formed good representation in susceptible isolates. The S family 
had over 40% of the MDR –TB isolates, zero XDR and drug-susceptible and mono-resistant 
patterns were equally distributed. The results of these eight predominant families are 
summarized in Table 2.3 and figure 2.7. There were no major differences in distribution of the 8 
predominant families within the seven regions of Johannesburg (Table 2.4).  
 
Table 2.3: Description of 8 predominant families (Clustered from 16 to 135 per Clade) from a 
total of 340 isolates.   
 
SITn 
 
Clade 
 
                                  Binary (Spoligotype) Description 
 
Total 
strains 
 
1 
 
Beijing 
 
 
 
135 
 
34 
 
S 
 
 
 
42 
 
60 
 
LAM4 
 
 
 
41 
 
53 
 
T1 
 
 
 
38 
 
33 
 
LAM3 
 
 
 
30 
 
50 
 
H3 
 
 
 
21 
 
48 
 
EAI1_SOM 
 
 
 
17 
 
92 
 
X3 
 
 
 
16 
 
 
c c c c c c c c c c c c c c c c c c c c c c c c c c c c c c c c c c g g g g g g g g g
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g g g g g g g g c c c g g g g g g g g g c c c c g g g g g g g g c c c c g g g g g g g
g g g g g g g g g g g g g g g g g g g g g g g g g g g g g g c g c c c c g g g g g g g
g g g g g g g g g g g g g g g g g g g g g g g g g g g g c c c c g c g g g g g c g g g
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64 
 
 
The eight predominant families represented (340/500) 68% of the total 500 isolates. The 
percentage for each of the eight predominant families is presented in figure 2.7  
 
Figure 2.8: Percentage representation for the eight predominant families. 
 
 
Table 2.4:    Distribution of the 8 predominant families in seven regions (A-G) of Johannesburg 
 
 
SIT 
 
Clade 
 
Region 
A 
 
Region 
B 
 
Region 
C 
 
Region 
D 
 
Region E 
 
Region F 
 
Region G 
 
1 
 
Beijing 
 
21 
 
20 
 
14 
 
37 
 
19 
 
22 
 
2 
 
34 
 
S 
 
7 
 
10 
 
6 
 
11 
 
3 
 
4 
 
1 
 
60 
 
LAM4 
 
2 
 
4 
 
4 
 
13 
 
8 
 
8 
 
2 
 
53 
 
T1 
 
8 
 
4 
 
5 
 
11 
 
3 
 
7 
 
0 
 
33 
 
LAM3 
 
5 
 
5 
 
3 
 
10 
 
3 
 
2 
 
2 
 
50 
 
H3 
 
0 
 
4 
 
3 
 
5 
 
5 
 
4 
 
0 
 
48 
 
EAI1_SOM 
 
1 
 
3 
 
3 
 
7 
 
3 
 
2 
 
0 
 
92 
 
X3 
 
2 
 
2 
 
2 
 
5 
 
0 
 
5 
 
0 
 
 
 
 
Beijing 
27% 
S 
8.4% 
LAM4 
8.2% 
T1 
8.2% LAM3 
6% 
H3 
4.2% 
 EAI1-SOM 
3% 
X3 
3% 
10.2% 
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Figure 2.9: Distribution of the eight predominant families within the five susceptibility patterns 
 
 
These eight predominant families were found to be greatly associated with drug-resistance with a 
p value of <0.001 when was statistically tested by chi-square test. Despite the fact that there were 
only eight predominant families, a number of small clustering (2 to 8) families were identified 
and the number of isolates for each family found in the study is presented in figure 2.9.  
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Figure 2.10: Distribution of the small clustering isolates  
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              Table 2.5:    Description of orphan isolates (n = 42). 
 
Binary (Spoligotype) description No. of isolates 
                   
 
 
              5 
 
 
 
              2 
 
 
 
             2 
 
 
 
             1 
 
 
 
             1 
 
 
 
             1 
 
 
 
             1 
 
 
 
             1 
 
 
 
             1 
 
 
 
             1 
 
 
 
             1 
 
 
 
             1 
 
 
 
            1 
 
 
 
            1 
 
 
 
            1 
 
 
 
            1 
 
 
 
 
 
 
 
 
 
 
               
g g g g g c g g g g g g g g g g g g g g g g g g g c c c c c c g c c c c g g g g g g g
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               Table 2.5:   continues. 
                                                           
Binary (Spoligotype) Description No. of Isolates 
 
 
 
             1 
 
 
 
             1 
 
 
 
             1 
 
 
 
             1 
 
 
 
             1 
 
 
 
             1 
 
 
 
             1 
 
 
 
            1 
 
 
 
            1 
 
 
 
            1 
 
 
 
            1 
 
 
 
            1 
 
 
 
            1 
 
 
 
            1 
 
 
 
            1 
 
 
 
            1 
 
 
 
            1 
 
 
 
            1 
 
 
 
            1 
 
 
 
            1 
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2.6.1 Recent transmission index results 
 
 
RTIn-1 = (nc-c)/n (where n  is the total number of cases in the sample, nc is the total number of 
cases in cluster while c  is the number of (cluster) genotypes represented by at least two cases) 
(Guernier et al. 2008). n = 500, nc = 436, c = 31. Therefore:  ([436 – 31]/500) X 100 = 81%. 
Based on the n-1 method as shown above and as explained in section 2.5.6.1, the recent 
transmission index showed that 81% of the isolates were recently transmitted. Out of 81%, 62% 
([340 - 31/500] x 100) represented the eight predominant families.  
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2.7 Discussion 
 
 
This study presents the largest amount of molecular epidemiological data on MTB isolates from 
seven regions of Johannesburg and is the first study to have typed the isolates of MTB that have 
varying patterns of susceptibility, from fully-susceptible to INH/RIF-mono-resistant, MDR, pre-
XDR and XDR. People from other regions of South Africa and other countries in Africa migrate 
to Johannesburg looking for work, and this migration may have an impact on the TB strains that 
are circulating in the area as some of the immigrants come from areas of high TB and drug-
resistant TB prevalence such as KwaZulu-Natal (KZN) in South Africa, (Houlihan et al. 2010)  
and Nigeria (Lawson et al. 2012a).  
 
Previous studies based in Johannesburg, have documented a high prevalence of MDR-TB in 
children (Fairlie et al. 2011) as well as a high prevalence of TB/HIV co-infection in adults (John 
et al. 2007). There is a need for information on the molecular epidemiology of MTB strains that 
are circulating in Johannesburg to determine which of them are associated with the high 
prevalence of drug resistant MTB and HIV. The findings would assist in tracing the source of 
infection and allow appropriate preventative measures that could potentially minimize or control 
the spread of the disease. We thus ought to describe the genetic diversity of 500 MTB isolates by 
spoligotyping. 
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Genotyping of the 500 isolates by spoligotyping revealed a wide genetic diversity. Comparison 
of the spoligotyping results with the SPolDB4 showed that the majority 92% (n=458) of the 
isolates belonged to 59 previously described shared types while 8% (n=42) were not found in the 
SPolDB4 database and were termed orphans. Of the 42 orphan isolates, 10 isolates were 
clustered into 3 groups (ranging 2 to 5) while 32 isolates were unique orphans. The 59 previously 
described shared types and the 3 shared types from orphan isolates formed 62 shared types.  
 
Of these 62 shared types, 31 shared types were clustered representing a cluster rate of 93%. Eight 
of the 62 clustered shared types (clustered from 16 to 135) constituted 68% (n=340/500) of the 
total number of isolates spoligotyped; these, were by far the most prevalent and they were 
comprised of Beijing (SIT 1), S (SIT 34), LAM4 (SIT 60), T1 (SIT 53), LAM3 (SIT 33), H3 
(SIT 50), EAI1_SOM (SIT 48) and X3 (SIT 92). The same predominant families were also 
identified in a genotypic study conducted in eight of the nine provinces from South Africa in 
2009 (Stavrum et al. 2009b). 
 
The origin of some of the eight predominant shared types is known while others are uncertain 
(figure 2.9). The Beijing family is considered to have originated from China where they were 
first identified in 1995 and were termed Beijing because the vast majority of these Chinese 
strains originated from TB patients residing in Beijing (van Soolingen et al. 1995; Wan et al. 
2011). Other studies have indicated that the Beijing genotype was already highly prevalent in 
areas surrounding Beijing from 1956 to 1960 and that these strains disseminated to the 
neighbouring Asian countries such as Mongolia, Thailand, South Korea and Vietnam, and later 
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to other countries (Toungoussova et al. 2002). The Haarlem family (SIT 50) is thought to have 
originated from Central America and the Caribbean and provides a possible link to the post-
Columbus European colonization. The T family remains an ill-defined family of MTB and 
although found worldwide was thought, to be more specific to Russia.  The X type is thought to 
have originated from the UK and the USA (Brudey et al. 2006). The LAM 3 (SIT 33) and EAI1-
SOM  (SIT 48) were first isolated in South Africa and Somalia respectively (Abadía et al. 2009; 
Said et al. 2012). The S (SIT 34) lack specificity, but LAM 4 (SIT 60) is frequently regarded as a 
South African strain since it was responsible for the TB outbreak in Tugela Ferry from KZN 
(Pillay & Sturm, 2007). This strain is a member of Euro-American family and was first described 
in this region in 1994 (Gandhi et al. 2013) 
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Beijing family 
     Showing areas where it is more prevalent 
SIT families which did not dominate in this study but have caused major 
outbreaks in other African countries and outside Africa 
 LAM11 – ZWE   
 CAS1 – DELHI 
 CAS1 – KILI 
        CAS 
 
Isolates which were not identified in this study but have caused major 
outbreaks in other African countries 
 LAM10 – Cameroon 
 T2 – Uganda                                                                                                    
Figure 2.11 Demonstrates differences in geographical distribution of spoligotyping families. Sources; (Demay et al. 2012; Easterbrook et al. 2004; 
Mulenga et al. 2010; Ani et al. 2010; Godreuil et al. 2007; Bazira et al. 2010)
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This study reveals that Beijing was the most predominant family in Johannesburg representing 
27% of all the isolates, and 40% of the eight predominant shared types. The Beijing family was 
further well represented in all seven regions of Johannesburg with minor variations in numbers. 
This family has also been identified in other parts of South Africa, Africa, Asia, Europe and 
South America (Said et al. 2012; Viegas et al. 2010; Abadía et al. 2009; Pang et al. 2012; Liu et 
al. 2011). In a study conducted in Cape Town, the Beijing family was well represented. Of the 
291 isolates obtained from children, 23% were of Beijing (SIT 1) genotype making it the most 
predominant family and its prevalence was noted to have increased from 13% in 2002 to 32.8% 
in 2003 (Cowley et al. 2008; Mlambo et al. 2008) indicating that this family is fast emerging. In 
another study conducted in the northern region of South Africa, the Beijing family was found to 
dominate in both North-West and Limpopo provinces (Said et al. 2012a). Similarly, in a study 
conducted in Pretoria, 28% of the study isolates belonged to the Beijing family, and formed the 
largest group (Hove et al. 2012). This indicates that the Beijing family is well represented in 
South Africa although it may not necessarily form a major group in all of the provinces (Stavrum 
et al. 2009b).  
 
The high proportion of Beijing strains in Johannesburg is a worrisome situation since there are 
numerous studies that have linked this family to rapid transmission of MTB (Cowley et al. 2008) 
and to drug-resistant TB (Judith et al. 2006; Johnson et al. 2010; Ghebremichael et al. 2010; 
Kubica et al. 2005; Toungoussova et al. 2002; Kisa et al. 2012). In this study, 48% of all Beijing 
isolates were drug susceptible, 14% were mono-resistant to either RIF or INH, 15% were MDR, 
4% were pre-XDR and 19% were XDR. This shows that approximately 55% of the Beijing 
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isolates were associated with drug-resistance and we may be tempted to link this family to drug-
resistance.  In a study conducted in Cape Town a similar association was found, with 18% of the 
Beijing isolates being drug-resistant (Marais et al. 2006).  In South Africa in 2008, 34% of XDR-
TB isolates were found to be the Beijing family and formed the largest group within the XDR-
TB isolates described (Mlambo et al. 2008). Despite the majority of studies showing an 
association of the Beijing family to drug-resistance, there are some studies which fail to confirm 
this (Alonso et al. 2010; Toungoussova et al. 2003) and in a recent South African study not even 
a single Beijing isolate was found to be drug-resistant (Pillay &  Sturm, 2010).  
 
Despite the Beijing family being well represented in all susceptibility patterns, the proportion of 
LAM (LAM 4) in pre-XDR and XDR-TB isolates showed an interesting trend. Ninety three 
percent of LAM 4 isolates were associated with drug-resistance (17% were MDR, 22% were pre-
XDR and 54% were XDR isolates), while only 7% were fully susceptible and no mono-resistant 
isolates were found. The spoligotype pattern of the LAM 4 isolates in this study is identical to 
that of the pattern described in the F15/LAM4/KZN strain (Pillay & Sturm 2007; E M Streicher 
et al. 2007)  and shows a lack of spacers 21 – 24, 33 – 36, and 40. 
 
The LAM 4 (SIT 60) (F15/LAM4/KZN) family, has been associated with drug-resistance in the 
KZN province of South Africa  where it is believed to have been in circulation since 1994 (Pillay 
& Sturm 2007). In a recent study from KZN, 83% of TB reinfection was due to LAM4 (Pillay & 
Sturm, 2007). Furthermore, this family was found to significantly contribute to the nosocomial 
infection in both HIV-positive and negative patients (Pillay & Sturm, 2010) and was responsible 
for the outbreak of XDR-TB in KZN where 98% of the patients, died. (Gandhi et al. 2006).  
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The circulation of S, T1 and LAM3 family strains in this study was not surprising since some of 
these families have been found dominating in other studies done in South Africa. Their presence 
in Johannesburg is likely as a result of movement of people from different regions. The S family 
was responsible for the exogenous reinfection for 63% of the patients with MDR-TB from a 
South African rural community (Andrews et al. 2008). The S family formed the second most 
predominant family in this study (8%), after the Beijing family. The association of this family 
with drug-resistance as suggested by Stavrum et al. 2009 was supported by the findings of our 
study where 71% of the isolates belonging to this family were of drug-resistant. Of these, 63% 
were MDR. It was found that no isolate belonging to the S family was XDR indicating that the S 
family is less associated with XDR. Our findings are in line with the study done on XDR-TB 
patients from four provinces (Limpopo, North West, Northern Cape and Gauteng) of South 
Africa where none of the S family was found to be XDR (Mlambo et al. 2008). In contrast only 
one isolate of S family was found to be XDR in a recent study done in the in the Eastern Cape 
(Klopper et al. 2013). There is a high possibility that 63% of the S family which were MDR 
might become XDR. Therefore, we cannot rule out this family from becoming one of the 
families contributing to the transmission of XDR-TB in Johannesburg in the near future. 
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It seems likely that the S family is widely spread throughout South Africa as it was also found to 
be one of the predominant families in a study from the Northern Province of South Africa (Said 
et al. 2012a). Similarly, the T1 family seems to be prevalent throughout South Africa especially 
within the Gauteng province (Stavrum et al. 2009; Hove et al. 2012). Hence circulation of T 
family in Johannesburg is not surprising.  
 
We detected the presence of LAM 3 (SIT 33) which is likely to be the same as F11 which was 
first described in Cape Town. Both, LAM3 (SIT 33) and F11 are characterized by lack of spacers 
9 to 11, 21 to 24 and 33 to 36 which appear to be a unique marker for this strain (Streicher et al. 
2007; Victor et al. 2004). The LAM3 (SIT 33) family was first described in South Africa in the 
Western Cape where it has shown to be a successful strain contributing to the TB epidemic 
(Victor et al. 2004). Currently, the LAM 3 family seems to be widely spread in South Africa as 
evidenced through several studies (Hove et al. 2012; Klopper et al. 2013; Said et al. 2012), and it 
has also been largely associated with drug-resistance (Streicher et al. 2004; Victor et al. 2004). 
Our findings could not support the association of LAM 3 (SIT 33) with drug-resistance as 13%, 
27% and 3% were mono-resistant, MDR and XDR respectively, while 57% were drug-
susceptible.  
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Despite 23 families (designated as small clusters ranging from 2 to 8 isolates) being not well 
represented (they formed 17% of the total isolates in this study), they were families which have 
been described in TB epidemics in other African countries. Examples include the LAM11-ZWE 
(SIT 59) which is interchangeably called the Southern Africa 1 (SAF1) strain (Eldholm et al. 
2006) and the CASI-Kili (SIT 21) strain. The LAM11-ZWE is known to contribute to the TB 
epidemic mainly in Zimbabwe where it was first described and in Zambia. From a study done in 
Zambia, a total of 22% of isolates belonged to the LAM11-ZWE SIT 59 family (Mulenga et al. 
2010). The same isolate was found circulating in a study performed in Zimbabwe (Easterbrook et 
al. 2004). The circulation of this isolate in both Zimbabwe and Zambia can be due to easy 
migration of people between these countries. South Africa is a popular destination for migrant 
Zimbabweans. However, the scarcity of the LAM11-ZWE family amongst isolates evaluated 
here could be due to the time needed before transmission can become well established. The 
CASI-Kili family which was not well represented in this study, is more prevalent in Tanzania as 
demonstrated in the two studies (Kibiki et al. 2007; Eldholm et al. 2006).  
 
 
The orphan strains were compared with other orphans found in different studies. Four isolates in 
our study matched orphan isolates found in Zambia (Mulenga et al. 2010) and three of these 
clustered together. The remaining thirty eight orphan isolates did not match any isolate from 
other studies. Further comparison of these orphan strains with other studies is necessary in order 
to establish whether these isolates are specific to Johannesburg or South Africa. 
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Studies of the same nature have been conducted in different African countries including South 
Africa‟s neibouring countries. These studies have demonstrated that different geographical 
locations are dominated by different strains which are responsible for the TB epidemic in that 
particular area. From a study done in Mozambique, the LAM9 and Beijing families were the 
most predominant genotype (Viegas et al. 2010). Similarly, in Zimbabwe, the LAM11-ZWE 
family was the most predominant (Easterbrook et al. 2004); this was also found in a study in 
Zambia (Mulenga et al. 2010). However, CASI-Kili and LAM11-ZWE families dominated in a 
study conducted in Tanzania (Kibiki et al. 2007). The geographical specificity of MTB strains 
(Figure 2.10) has also been demonstrated from other studies done from Nigeria, Cameroon, Chad 
and Burkina Faso where LAM10-CAM is the most predominant family (Ani et al. 2010; 
Kamgue et al. 2013; Diguimbaye et al. 2006; Lawson et al. 2012b; Godreuil et al. 2007). 
 
 
Some of the predominant genotypes which we found in our study, such as the Beijing and LAM 
4 (SIT 60) families were not predominant in other African countries. It was noted that in all of 
the above mentioned studies done in Zimbabwe, Zambia, Tanzania, Uganda, Nigeria, Cameroon 
and Chad, the LAM4 family was not identified. It was detected in a study performed in 
Mozambique (Viegas et al. 2010). We may be tempted to say LAM4 (SIT 60) is not present in 
these countries but rather that this family is more prevalent in South Africa and particularly KZN 
and Johannesburg. Despite the Beijing family‟s wide spread, it does not seem to be predominant 
in many other African countries (Ghebremichael et al. 2010).  
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Our study did not identify some of the families which are dominating in other African countries 
such as LAM 10 (The Cameroon type) that dominates in Cameroon and Nigeria (Ani et al. 2010; 
Kamgue et al. 2013) and in other West African countries including Benin, Senegal and Ivory 
Coast (Godreuil et al. 2007). Our study also did not detect the most predominant family in 
Uganda, the T2-Uganda family (Bazira et al. 2010). The geographical specificity of these strains 
probably indicate that the difference in geographical location have an impact on the 
epidemiology of TB. It may be suggested that adaptation of particular lineages of MTB to human 
populations or geographical areas are different. It is thus suggested that local strains are more 
likely to transmit in a given local setting than compared to others (Bazira et al. 2010). 
 
It is a surprising that the Cameroon strain (LAM 10) which dominates in Nigeria was not found 
in this study since Johannesburg accommodates a large number of Cameroonians and Nigerians. 
The explanation could be that, these individuals, as foreigners, might prefer to seek health 
services in private settings which do not necessarily refer specimens to the NHLS TB referral 
Laboratory and as a result, they did not form part of this study.  
 
 
A high cluster rate of 93% was found in this area indicating that these spoligotype families 
greatly contribute to the transmission of TB in Johannesburg and that there is an ongoing 
transmission of TB taking place in this area. However, this has to be interpreted with caution 
since spoligotyping used alone is less discriminatory than when used in combination with other 
genotyping methods such as RFLP IS6110 and Mycobacterial Interspaced Repetitive Unit 
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(MIRU) (Kisa et al. 2012) even though some studies have demonstrated a strong correlation 
between results of Spoligotyping, MIRU and RFLP IS6110 genotyping results (Dou et al. 2008; 
Toungoussova et al. 2002).      
 
 
The study has shown a wide genetic diversity of strains circulating in the Johannesburg area. 
This could indicate that the incidence of TB in Johannesburg is not due to clonal transmission 
but rather that there is a wide range of strains contributing to TB transmission in the area. All 
strains were well represented in all seven regions, with minor variation in numbers and as a 
result there was no strain found to be specific to a particular area.  
 
 
Despite that the effort was made to have good sample selection criteria and a well represented 
study sample number, we still had some limitations. Firstly, we couldn‟t be able to select equal 
number of isolates from each region. This was due to the fact that other regions had few isolates 
per sensitivity pattern which qualified for the study. Never the rest, results were well represented. 
Secondly, we could not be able to justify if all patients entered in this study indeed got infected 
during their stay in Johannesburg to know if the transmission index we are having is a true 
representation of what is happen in the Great Johannesburg Metropolitan Area. Thirdly, we 
could not be able to link patients who had identical genotypes despite having demographic data. 
There was no actual visit of the patients to gain more information i.e. where he/she has lived 
before, history of hospitalization, etc in order to establish transmission routes. This was a big 
challenge as it could have formed another big study requiring additional financial support and 
extending study duration. We propose that in future, a similar kind of study should be conducted. 
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Chapter three: DNA Fingerprinting of Mycobacterium tuberculosis through 
IS6110 RFLP 
 
 
3.1 Introduction 
 
 
Mycobacterium tuberculosis has challenged medical researchers for decades by their failing to 
completely eradicate this disease as it continues to kill millions of people each year. The disease 
has been more extensively studied than any other infection caused by a bacterium. Despite all the 
effort, there is little sign and hope that the disease will soon end. The situation is more 
complicated with the emergence of Multidrug-resistant tuberculosis (MDR-TB) and the 
extensively drug-resistant tuberculosis (XDR-TB) (Brudey et al. 2006). In depth understanding 
of TB transmission dynamics, source and spread is need and this can be essential to control or 
stop the spread of the disease. Molecular epidemiological studies for TB are giving more hope 
than traditional studies to shade light on disease dynamics  (Wang et al. 2012). 
 
 
The IS6110 RFLP fingerprinting was included in the study to confirm the relatedness of a subset 
of clustered isolates by spoligotyping. We also wanted to see the correlation of results between 
the two methods; IS6110 RFLP and spoligotyping. Only a subset of isolates were fingerprinted 
because this was the first study to setup RFLP procedure in the department as a result a lot of 
challenges were met. This made it impossible to include a large sample size.  
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Various DNA fingerprinting methods differentiating strains belonging to the Mycobacterium 
tuberculosis (MTBC) have been developed after the discovery of the transposable elements and 
other repetitive DNA elements in MTBC in the early 1990s. Some of these are PCR based which 
is achieved by the amplification of repetitive DNA sequences, while other methods are based on 
the visualization of the restriction fragments containing particular repetitive DNA elements such 
as insertion sequence (IS) elements (Friedman et al. 1995; Plikaytis et al. 1993; van Soolingen et 
al. 1994; Wiid et al. 1994). A comparison of these two methods, the spoligotyping and 
Restriction Fragment Length Polymorphism (RFLP) typing methods, showed that IS6110 RFLP 
has a high discriminatory power and is reproducible (Wiid et al. 1994; Narayanan 2004).  
 
 
The international standardization of the RFLP method with regard to the choice of restriction 
enzyme, probe, and size markers has enabled interlaboratory comparison through 
computerization of DNA fingerprints (van Embden, 1993). The presence of the IS6110 element 
in different copy numbers, integrated at various chromosomal sites and the molecular weights of 
the DNA fragments, provides enough information regarding transmission dynamics of MTB 
(Kim et al. 2010). It is because of this high discriminatory power that the IS6110 RFLP has been 
applied in different geographical locations for the management of MDR-TB and in population 
based molecular epidemiological studies (Edlin et al. 1992) . With several studies done 
worldwide, the molecular epidemiology of  MTBC through IS6110 RFLP provided insight into 
risk factors for the transmission of TB and the spread of particular MTB genotypes families in 
different regions (Small et al. 1994; Alland et al. 1994; Yang et al. 1995; Pfyffer et al. 1998).  
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3.1.1 General overview of the IS6110 
 
 
The IS6110 is a genomic insertion element containing 1,361 bp that is found only in species 
within the organisms Mycobacterium tuberculosis complex (MTBC) (Kim et al. 2010). The 
IS6110, IS986 and IS987 limited to mycobacterial species belonging to the MTBC, have been 
characterized and sequence analysis has revealed that they differ in only a few base pair. 
However, they are considered to be virtually identical (van Embden et al. 1993; Hermans et al. 
1991; Thierry et al. 1990). The copy number of the IS6110 element varies between the members 
of the MTBC. While the M. bovis BCG genome contains one or two copies of IS6110 (van 
Soolingen et al. 1991; Hermans et al. 1991), the genome of Mycobacterium tuberculosis has 
between 0 and 25 copies of this element (Kim et al. 2010). The sequence of the element 
designated IS6110, was first reported by Thierry et al. in 1990 and was shown to be related to the 
IS3 family of insertion sequences which were discovered in members of the family 
Enterobacteriaceae.  
 
 
The structural organization of the 1,361 bp long has 28 bp of imperfect inverted repeats (IRs) 
and duplications that are 3 or 4 bp in length next to the insertion site. It has two partially 
overlapping reading frames (ORFs), orfA and orfB, that encode a transposase allowing the 
insertion of IS6110 at multiple sites (figure 3.1) (Kim et al. 2010). The ORFs (orfA and orfB) of 
IS6110 are similar to the ORFs (orfA and orfB) of IS3 found in prokaryotes (Mendiola et al. 
1992).  The physical map of the IS6110 sequence (figure 3.1) indicates that various restriction 
enzymes; (BamHI, SstII, PstI, BstEII, BssHII, and PvuII) cleave within the 1,361-bp element. 
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The PvuII enzyme has successfully been used in RFLP and is considered to be the standard 
enzyme used in the majority of laboratories performing RFLP as it cleaves the IS6110 sequence 
only once. The PvuII digestion of IS6110-containing genomic DNA leads to IS6110-
hybridization fragments of at least 0.90 or 0.46 kb, depending on the IS6110 probe that is used 
(van Embden et al. 1993). 
 
 
                    
 
 
 
 
Figure 3.1: 
Adapted from van Embden et al. 1993. 
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Although the IS6110 is a transposable element, with the potential to translocate within the 
chromosome, it is stable enough to provide identical restriction fragments for mycobacterial 
strains from within small clusters of infection (Yuen et al. 1993) and several studies have 
demonstrated the stability of this element (Hermans et al. 1991; Mathema et al. 2006b). Apart 
from being used as a molecular epidemiological marker, the IS6110 is considered to have 
different functions, including the activation of genes during infection (Safi et al. 2004; van 
Embden et al. 1993; Soto et al. 2004). Finally, it has been suggested that the presence of IS6110 
in M.bovis could participate in the adaptation of this bacteria to a particular host, either animal or 
human (Otal et al. 2008). 
 
 
Despite IS6110 RFLP typing being considered the gold standard for characterizing the molecular 
epidemiology of MTBC, the method is technically demanding and requires 4-8 weeks to culture 
isolates in order to obtain pure and sufficient DNA. In addition, it provides insufficient 
discriminatory power particularly for isolates with less than 6 copy numbers of IS6110. Although 
this method provides excellent differentiation, it requires specialized software for analysis of the 
data and results in a relatively long turnaround times for reporting of the results. (Kehinde, 2012; 
Narayanan, 2004). 
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The epidemiological analysis of MTB by IS6110 DNA fingerprinting is based on the observation 
that the polymorphism of the IS6110 RFLP patterns among unrelated clinical isolates is very 
high, whereas epidemiologically related MTB strains show identical or similar (one band 
variation) fingerprint patterns. Hence, MTB isolates with identical fingerprint patterns represent 
strains that have possibly been recently transmitted, and these strains are likely to involved in a 
chain of transmission (Niemann et al. 1999) 
 
 
The purpose of this RFLP portion of this study was to fingerprint a subset of the related MTB 
isolates previously found through spoligotyping to confirm the isolate relatedness and categorize 
them according to their respective families. Furthermore to correlate the IS6110 RFLP 
fingerprinting results with the spoligotyping results and to establish transmission routes through 
clustered predominant clones circulating in the great Johannesburg metropolitan area.  
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3.2 Materials and Methods 
 
 
 
3.2.1 Sample identification and selection 
 
 
Sample identification and selection was done as previously described. Please refer to chapter 2, 
sections 2.2.3.1 and 2.2.4.2 
 
 
 
3.2.2 Sub-culturing of Mycobacterium tuberculosis on LÖwenstain Jensen medium  
 
 
Seven drops (50µl) of each isolate from a MGIT vial was inoculated onto LÖwenstain Jensen 
slants using a sterile 1 ml Pasteur pipettes. The slants were left facing upwards and the lids 
slightly loose and incubated (Labcon incubator, Laboratory marketing services, RSA) at 37°C 
for 24 hours, after which the lids were kept tightly closed. The LJ slants were aerated after every 
2 days for 2 weeks, two times a week during the third and fourth week, and once a week from the 
fifth week to the eighth week depending on the growth observed. Growth was indicated by 
formation of granular white/cream colonies on the slants. 
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3.2.3 Isolation of genomic DNA 
 
 
3.2.3.1 Extraction 
 
 
The LJ slant cultures were heat-inactivated at 80˚C for 1 hour in a Biological safety class II 
cabinet before DNA extraction was performed. The heat-inactivated growth from a slant culture 
was scraped off and suspended in 1.5 ml of distilled water thereafter it was transferred into a 
sterile 2ml conical screw cap microtube which contained three 5 mm glass beads. The bacterial 
clumps were broken up by vigorous vortexing of the tube for approximately 2 minutes. The tube 
was then centrifuged (Eppendorf, Hamburg, Germany) at a speed of 7000 xg for 5 minutes and 
the supernatant removed. Cell lysis was achieved by resuspending the cell pellet in 400 ul TE 
buffer (5ml 1M Tris-Cl, pH 8.0 and 1ml 0.5M EDTA) into which 50 ul of Lysozyme [10mg/ml 
(0.5g Lysozyme plus 50ml 10mM Tris-Cl, pH, 8.0)] was added and gently mixed by inverting 
the tube several times before overnight incubation (MWG-Biotech Mini Oven MKII) at 37˚C.  
 
3.2.3.2 Purification of DNA 
 
After overnight incubation, purification and precipitation of the DNA was performed. Seventy 
five microliters of SDS/Proteinase K (10%SDS plus 10mg/ml of proteinase K. 14:1 ratio 
respectively) was added into each tube containing the cells. The contents were mixed by gentle 
inversion and then incubated at 65˚C for 1 hour. After incubation, 100 ụl 5M NaCl and 100 ụl 
CTAB/NaCL (pre-warmed to 70˚C) was added to each tube. The tubes were vortexed for 10 
seconds until the solution became milky, and then incubation for 20 minutes at 65˚C. It was then 
allowed to cool at room temperature for 5 minutes before the addition of 750 ụl Chloroform-
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Isoamyl alcohol (24:1 ratio respectively to remove CTAB-protein/polysaccharide complexes). 
The tubes were thoroughly mixed by inversion followed by centrifugation at 7000 xg for 15 
minutes. The upper/aqueous phase containing the DNA was transferred into a new sterile conical 
screw cap microtube.  
 
Precipitation of the DNA was achieved by adding 500 ụl of ice-cold isopropanol into each tube. 
This was carefully mixed by inverting and DNA precipitation could be seen at this stage before 
freezing at - 80˚C for 30 minutes.  
 
After the freezing process, the precipitated DNA was left at room temperature for 30 minutes 
before being centrifuged for 15 minutes at 7000 xg (Eppendorf, Hamburg, Germany). The 
supernatant was gently removed by pipetting.  A volume of 1ml of cold 70% ethanol was added 
and centrifuged at 7000 xg for 15 minutes. The supernatant was again carefully removed with a 
sterile Pasteur pipette. The pellet was left to dry at room temperature for 4 hours. Finally, the 
DNA was dissolved in 50 ụl 1 X TE buffer at 37˚C for 2 to 3 three hours. The quality and 
quantity of DNA was determined spectrophotometrically (Nanodrop 2000 Spectrophotometer) 
and by running the DNA on 1% (TBE buffer) agarose gel. 
 
3.2.4 Digestion of genomic DNA 
 
 
RFLP was performed using the standardized IS6110 technique (van Embden et al. 1993). The 
extracted genomic DNA was digested with PvuII in a reaction mixture consisting of  6 ụg  DNA, 
10 ụl 10X buffer (Fermentas, Life Sciences), 3 ụl (30units) PvuII enzyme (Fermentas, Life 
Sciences) and made up to 100ụl volume with distilled water. The restriction mixture was 
91 
 
incubated overnight (16 hrs) at 37˚C. The PvuII enzyme activity was inactivated by incubating 
the digested sample at 65˚C for 15 minutes.  
 
An aliquot of 10 ụl of PvuII digest products mixed with 4 ụl 6 X loading buffer, was run on 1% 
(w/v) Seakem® ME agarose gel (BioWhittaker molecular applications, USA) at 30 Volts in 1 X 
TBE (g/l 21.6g Tris, 11 g Boric acid, 1.5 g EDTA, pH 8.3) buffer for (16hrs) overnight to test for 
the completion of digestion. The gel was stained with ethidium bromide solution (50 ụl of 10 
mg/ml of ethidium bromide, 500 ml of 1 X TBE buffer) and DNA pictures were visualised using 
the BIO-RAD Gel documentation system (BIO-RAD, USA).  
 
3.2.5 Sample preparation for the final gel and electrophoresis 
 
The PvuII digested DNA was neutralized and precipitated by adding 10ụl 3M Sodium acetate 
and 330ụl ice cold 100% ethanol to the remaining 90 ụl of the PvuII digested product and 
incubated for overnight at -20˚C. Samples were centrifuged at 4˚C using refrigerated centrifuge 
(Hettich Zentrifugen, Universal 16R, 31603-M13-01, Germany) at a speed of 10 000 xg for 30 
minutes. The supernatant was aspirated 500 ụl of 70% ice cold ethanol was added to the DNA 
pellet. This followed another centrifugation and aspiration of the supernatant step. The DNA 
pellet was air dried overnight.  Re-dissolving of DNA was achieved by adding loading buffer 
containing Internal Molecular Weight Marker (IMWM). The amount of buffer to add into each 
sample was calculated based on the intensity of DNA seen in the test gel.  A 0.8% Seakem® ME 
agarose gel (20 cm
2
) was prepared and loaded with 15ul of the re-dissolved DNA. The reference 
strain (Mt 14323) was used as external marker which was loaded in the first well and middle 
well of the gel. Fragments of DNA were separated by gel electrophoresis in 1 X TBE buffer at 
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30 V for 18 hrs. Denaturing of DNA in the gel was achieved by agitating the gel in 500 mL 
depurination solution (0.25N HCL) for 10 minutes, then in 500 mL of denaturing solution (0.4N 
NaOH / 0.6M NaCL) for 40 minutes and finally in 500 mL of neutralization buffer (1.5M NaCL 
/ 0.5M Tris pH 7.5) for 30 minutes. The gel was rinsed with distilled water between each step. 
The gel was stained with ethidium bromide and visualized as mentioned in section 3.2.3.  
 
 
3.2.6 Southern transfer of the DNA 
 
Transfer of the DNA fragments from the gel onto a Hybond-N
+
 membrane (Amersham Life 
Science) was achieved through the Southern transfer technique. Whatman 3MM paper pre-
soaked in 20X SSPE was set in a clean plastic tray where the inverted agarose gel was placed on 
with edges as well as the wells removed with a sterile surgical blade. Air bubbles were removed 
by rolling a 10 mL serological pipette over the gel. Orientation of the membrane was achieved 
by spotting it with an orientation marker (3 ụl of the Mt 14323 strain, 3 ụl of IMWM, 45 ụl of 
0.8% of NaOH) on the top and bottom of the membrane. The membrane was hydrated in distilled 
water before being placed on top of the gel. Two layers of Whatman 3MM blotting paper, pre-
wetted in 20X SSPE (3M NaCL, 0.2 M NaH2PO4, 20mM EDTA) pH 7.4 were placed onto the 
Hybond-N
+
 membrane and again air bubbles were removed. To ensure fluid flow through the 
agarose gel, folded paper towels were stacked onto the Whatman 3MM papers. The contact was 
enhanced by the addition of a glass plate and a 1 kg weight. The blotting tray was filled with 20X 
SSPE (pH 7.4) with the first layer of blotting papers three-quarter immersed in the transferring 
solution. The Southern transfer was run for at least 16 hours. After transfer, the Hybond-N
+
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membrane was washed in 2X SSPE for 10 minutes thereafter it was baked at 80˚C (between 2 
sheets of Whatman 3MM blotting paper) for 2 hours to fixed the DNA to the membrane. 
 
 
3.2.7 Preparation of the IS6110 Probe 
 
Two microliters of a (Mt 14323) DNA probe was used as template for amplification of 245-bp 
fragment. The reaction was carried out in 50 ul volume consisting of 25 ul PCR master mix 
(Fermentas-Life Sciences), 5 ul of forward primer (INS 1, 5΄ 
CGGGGGGGCGGCGGGGGGGC), 5ul of reverse primer (INS 2, 
5΄GCGTAGGCGTCGGTGACAAA), and 13 ul of distilled water. Thermal cycling (Bio-rad, 
iCycler Thermal Cycler, USA) were as follows: 94˚C for 5 minutes (denaturing) followed by 30 
cycles of 94˚C for 30 seconds, and 65˚C for 30 seconds. A final extension step at 72˚C for 10 
minutes followed. Amplification was confirmed by running a small volume of the product on a 
0.8% agarose (Seakem, Lonza, Rock land, ME USA) gel. After confirmation of amplification, 
the amplified probe was purified using the GeneJET
TM
 Gel Extraction Kit (Fermentas, Vilnius, 
Lithuania). The purified DNA probe was diluted to 10ng/mL with 0.1X TE buffer.  
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3.2.8 Hybridization with ECL Kit (Amersham Biosciences) 
 
3.2.8.1 Labelling of the probe 
 
Twenty microliters of the diluted DNA probe was placed in a microfuge tube and denatured by 
boiling for 10 minutes in a beaker containing water. It was immediately cooled on ice for 10 
minutes and briefly spun to collect the contents at the bottom of the tube. Twenty microliter of 
the labelling reagent was added to the cooled DNA probe followed by 20 ul of glutaraldehyde 
solution. The mixture was incubated in a heating block (Labnet, Edson, NJ) for 20 minutes at 
37˚C.   
 
 
3.2.8.2 Hybridization 
 
 
Hybridization was performed in a rotating hybridization oven (MWG-Biotech Mini Oven MKII). 
The membrane was briefly rehydrated in 500mL of distilled H2O before it was placed in a 
hybridization tube (MWG – Biotech AG, Ebersberg, Germany). The membrane was then 
covered with 50mL of pre-warmed (42˚C) hybridization buffer (Amersham Biosciences, 
Buckinghamshire, UK) and prehybridized for one hour at 42˚C. The labelled IS6110 probe was 
then added and hybridization continued overnight at 42˚C. Hybridization of the membrane with 
the IMWM was done in a sealed plastic bag containing 50mL of hybridization buffer. A 500mL 
of water in a sealed plastic back was placed on top of the bag containing the membrane. Pre-
hybridization was done at 42 ˚C for one hour in an incubator (Incubator Shaker, 25 series, 
Edison, New Jersey, USA). The labelled IMWM probe was added to the buffer and hybridized 
for overnight. 
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3.2.8.3 Post-hybridization 
 
 
Stringency wash of the membrane was done immediately after hybridization. The hybridization 
buffer was removed and replaced with 100mL pre-warmed(42˚C) primary buffer (360g Urea, 
25mL 20X SSC, 20mL 20% SDS, 1000mL distilled H2O) and washed twice for 30 minutes each 
in the hybridization oven at 42˚C. Finally, it was washed twice with 500mL secondary washing 
buffer (100ml 20X SSC, 800mL DH2O) at room temperature for five minutes each on a shaking 
platform (Labcon shaker, Laboratory marketing services, RSA).  
 
 
3.2.8.4 Signal generation and detection  
 
 
Signal generation and detection was done according to the ECL kit (Amersham Biosciences, 
Buckinghamshire, UK) following manufacturer‟s instructions. After washing the membrane with 
the secondary buffer, the membrane was put in a clean plastic bag with the DNA facing upwards. 
Excess secondary wash buffer was removed by rolling a 10mL serological pipette over the 
membrane. Equal volumes of ECL detection reagents one (5mL) and two (5mL) were mixed and 
poured directly on the membrane on the DNA side. It was evenly spread by rolling with a 10 mL 
serological pipette for 90 sec. Excess detection fluid was removed as explained above. The 
sealed membrane was placed in an X-ray cassette. Exposure to the film (Amersham Biosciences, 
Buckinghamshire, UK) was done in a darkroom at the Radiology Department at the Charlotte 
Maxeke Johannesburg Hospital, and developed using a Kodak RPX – OXMAT processor 
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(Eastman Kodak Company, New York, USA). The exposure time ranged from 1 hour to 16 
hours. 
 
3.2.8.5 Stripping the membrane 
 
The probe was effectively removed by placing the membrane in a flat plastic container 
containing 500 mL of boiling 0.1% SDS. It was incubated with gentle shacking for 60 minutes or 
until the solution reached the room temperature. 
 
 
3.2.9 Analysis of IS6110 RFLP patterns    
 
 
The analysis of RFLP profiles was achieved by using the computer software Gelcompar II, 
Version 2.5 (Applied Maths, Kortrijk, Belgium). The DNA fingerprints were analyzed using the 
Dice coefficient unweighted pair-group method with arithmetic averages (UPGMA). Analysis of 
the RFLP profiles was done at University of Stellenbosch, Division of Molecular Biology and 
Human Genetics, Cape Town. 
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3.3 Results for the IS6110 RFLP   
 
 
A subset of 74 MTB isolates from 500 isolates were randomly selected from each sensitivity 
category as presented in chapter two section 2.6, figure 2.5. These isolates were previously 
genotyped through spoligotyping. RFLP analysis of 74 MTB isolates was performed using 
IS6110 as a probe. The copy number of IS6110 for each isolate was determined from the number 
of bands hybridizing with the probe. The fingerprint patterns on the resulting autoradiographs 
were scanned and analyzed using Gelcompar II, Version 2.5 (Applied Maths, Kortrijk, Belgium).  
 
The study showed that eighty percent (59/74) of the isolates had their fingerprint patterns 
available in the database and the predominant families identified through IS6110 RFLP 
corresponds to the families identified through spoligotyping. 
 
Thirty distinct RFLP patterns were revealed from 74 MTB isolates and results showed highly 
variable IS6110 fingerprinting patterns (figure 3.2 and figure 3.3) with copy number ranging 
from 0 to 22. Fifteen isolates could not be identified and were assigned a study identification 
family name (E-T) (figure 3.2) Six of these isolates designated FOE, FOF, FOG, FOH, FOI and 
FOJ, were previously classified as orphans through spoligotyping.  
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A figure below presents isolates which did not exist in the database. Three isolates had zero copy 
number of IS6110 of which one was an orphan. 
 
 
 
Figure 3.2: number of isolates which did not exist in the database. 
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Figure 3.3: representation of IS6110 fingerprints on the X-ray film. 
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Figure 3.4: description of IS6110 RFLP patterns and the corresponding families by Gelcompar II for one 
membrane. 
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Of the thirty obtained RFLP fingerprint patterns, 15 (20%) were represented by a single isolate 
from which 3 (4%) had zero copy number. The cluster range for the 12 RFLP patterns, was from 
2 to 10 (figure 3.3). The largest RFLP cluster pattern, which comprised of 12 isolates, where 
designated F29, also known as Beijing family. This was closely followed by F15, commonly 
known as F15/LAM4/KZN and F9 which is also a LAM4 family. The fingerprints for all isolates 
which were not classified by Gelcompar II were visually compared. 
 
The clustering percentage of the isolates was considerably high at 82% (61/74), which may 
suggest cases representative of recent transmission, while the 13 unique isolates may indicate 
epidemiological independence or recurrent infection. The proportion of isolates with low copy 
number of six or less was determined to be 9%.  
 
 
Figure 3.5: IS6110 RFLP patterns clustered from 2 to 10. 
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Comparison of the results for the two methods showed that 56 isolates had identical IS6110 
RFLP patterns as well as spoligotypes. Nine isolates which were clustered by spoligotyping were 
later splinted by IS6110 RFLP fingerprinting.  
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 3.4 Discussion  
 
Molecular epidemiology of MTB has gained worldwide acceptance over traditional techniques. 
DNA finger printing of Mycobacterium tuberculosis through the study of the IS6110 element is 
still considered the gold standard despite the cumbersome and costly nature of the procedure. In 
the present study, the IS6110 RFLP was used to fingerprint 74 MTB isolates. To the best of our 
knowledge, at the time of writing this report, this study is the first to have typed MTB isolates 
from the great Johannesburg metropolitan area through IS6110 RFLP.  
 
RFLP was performed on a subset of isolates previously classified by spoligotyping. The isolates 
were randomly selected from each spoligotype cluster and included a subset of isolates classified 
as orphans and a few isolates which did not cluster. Inclusion of the orphan and non-clustering 
isolates were to establish whether they could be distinguished through IS6110 RFLP.  
 
Results for spoligotyping of the same 74 MTB isolates which were again analysed through 
IS6110 RFLP, revealed a total of 25 distinct patterns. Of these, 14 were singly represented with 
the remaining 60 isolates being grouped into 8 clusters. Six of the unique isolates were absent in 
the spoligotyping database and were described as orphans while 8 isolates belonged to different 
spoligotyping groups. The largest spoligotyping cluster contained 22 isolates belonging to 
Beijing family seconded by LAM4 SIT 60 with 20 isolates.  
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Analysis of these 74 MTB isolates by IS6110 RFLP fingerprinting technique generated 30 RFLP 
patterns and showed that 80% (59/74) of the isolates from this study matched the fingerprints 
found in the IS6110 RFLP database. The copy number for the IS6110 element varied from 0 to 
22 in each of the isolates. Thirteen isolates, however, did not exist in the database and of these; 
six isolates had a low copy number of IS6110 element of six or less. Furthermore, five were 
isolates that were previously described as orphans by spoligotyping, of which one had zero copy 
number and two isolates belonging to Beijing family, also had zero copy number of the IS6110 
element. All the orphan isolates included in this study did not match any fingerprint in the 
IS6110 database hence were not classified to a family. Only two isolates containing low copy 
number were able to be classified as F120 and F130 while the other 4 isolates were absent in the 
database.  
 
 
The RFLP analysis grouped 59 isolates into 12 clusters, 8 of which are presented in figure 3.6. 
The largest cluster contained 12 isolates belonging to F29/Beijing family and was followed by 9 
isolates within F15/LAM4 SIT 60 family. The correlation of the results between the two typing 
methods (figure. 3.6) was found to be 76% (56/74). It was further observed that the IS6110 
RFLP fingerprinting subclustered the spoligotyping clusters Beijing and LAM4 SIT 60 into two 
subclusteres each. The Beijing family was categorized into F29 and F31 while LAM4 SIT 60 
was categorized into F15 and F9 even though the F29 and F15 were still the predominant 
families. It was also noted that spoligotyping had classified 5 isolates as H3 SIT 50 but these 
were subclustered by RFLP fingerprinting into three subclusters. Two isolates were classified as 
F2, the other two as F4 and one isolate was absent from the database. In another note, one isolate 
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classified by spoligotyping as an unknown isolate (SIT 34 U likely S) was identified as F28 
together which paired with the S type families. The tendency of IS6110 RFLP fingerprinting to 
split spoligotype clusters, has also been observed in other studies (Goyal & Saunders 1997) 
while it has also been demonstrated to have a good correlation between the two molecular typing 
techniques (Toungoussova et al. 2003; Gandhi et al. 2006).  
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IS6110 RFLP description (Gelcompar II) 
 
 
 
 
Binary description of spoligotyping (SpolDB4.0) 
 
 
 
RFLP 
Family 
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Figure 3.6: Correlation of IS6110 and Spoligotyping results. The relatedness of strains is shown by forming a cluster in both methods.  
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Combination of the two molecular techniques in the study of TB epidemiology in order to 
confirm the strain relationship, is imperative as suggested by Niemann et al. 1999 and Filliol et 
al. 2002. This notion is also supported by our study findings reported here. It was observed that 
the discriminatory power for the two molecular techniques differ as indicated by Filliol et al. 
2002 and Goyal & Saunders 1997. Spoligotyping may be seen as the method of choice for 
isolates with low copy number (six or less), as discrimination among these isolates tend to be 
good. Out of six isolates with a low IS6110 copy number, only two were described which might 
be due to poor discriminatory power of the IS6110 fingerprinting technique in isolates with a low 
copy number. In a different note from this study, spoligotyping never subclustered the Beijing 
SIT 1, LAM4 SIT 60 and H3 SIT 50 family, but these clustering families were subclustered by 
IS6110 RFLP fingerprinting as explained above. Although the IS6110 RFLP fingerprinting 
might have shown a high discriminative power in Beijing family, other studies recommend the 
use of spoligotyping when distinguishing Beijing isolates from other isolates since the IS6110 
RFLP pattern of the Beijing strains is not unique (Burgos &  Pym 2002). Much as we know that 
the two molecular techniques target different molecular markers, then these minor differences 
should be accepted.  
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The presence of these isolates in the database shows that apart from Johannesburg, they are also 
in circulation elsewhere within South Africa and abroad. In addition, the IS6110 RFLP findings 
are confirming the spoligotyping results. The F29, F15, F28 and F11 have shown to be common 
in South Africa. The F29, F15 and F11 are interchangeably called Beijing, LAM 4 SIT 60 and 
LAM 3 respectively after confirming the genomic similarity (Richardson et al. 2002; Nicol et al. 
2005; Naidoo & M Pillay 2013; Ferry et al. 2011). The F29, F28 and F11 shows to have been in 
circulation at least a decade ago (Richardson et al. 2002). These families were the most 
predominant families in a study conducted in Western Cape, South Africa in which F29 was 
confirmed to be a member of Beijing family (Richardson et al. 2002). It now seems apparent that 
they are still in circulation as demonstrated by results presented here as well as from the recent 
studies (Naidoo &  Pillay 2013). The presence of these strain families in Johannesburg is not a 
surprise with migration of people to and from different provinces of South Africa including 
immigrants from cross borders. Our study has indicated that these isolates are one of the most 
successful strains causing TB epidemic in Johannesburg and in other provinces from South 
Africa.  
 
 
The Beijing family has shown to be the most successful isolate in the world. This family through 
IS6110 RFLP fingerprinting can be divided into seven lineages progressing from ancestral to 
modern. This family is well established in Johannesburg and in other provinces of South Africa 
as mentioned earlier on. The F29/Beijing was found to dominate in a study done in Cape Town 
in patients with mix strain cultures and it formed a large endemic cluster (Richardson et al. 
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2002). The F29 belong to lineage 6 and it is considered to be modern lineage. Though lineage 7 
is considered as the most prevalent in Western Cape, the F29 through its sublineage R220 is 
overrepresented among drug-resistant isolates in the Western Cape of South Africa (Ioerger et al. 
2010). This family (F29) is also considered as part of the globally relevant Beijing family 
(Richardson et al. 2002).  
 
 
The description of the F15 found in this study has been confirmed to F15/LAM4/KZN also 
described by Pillay & Sturm 2007 and Ferry et al. 2011. Both molecular markers (IS6110 and 
Spoligotyping) used in this study matched the description of F15/LAM4/KZN. The presence of 
this family in Johannesburg poses a major challenge to the National TB program (NTP). This 
family is largely associated with XDR-TB which is very difficult to treat (Banerjee et al 2008). It 
has shown to be common in South Africa as it has been described in many studies conducted 
around country. From a study done in KZN the F15 family formed the largest group among 
MDR-TB patients. Of the 109 patients suffering from TB infected with the F15/LAM4/KZN, 
59% were suffering from MDR-TB. Again, in 2005 in one district of KZN, 59% of the 102 TB 
were suffering from MDR-TB infected with the F15/LAM4/KZN strain (Pillay & Sturm 2007b). 
From another study of XDR-TB done in Tugela ferry where 98% (52/53) of the infected people 
died, it was confirmed that 85% were infected with this (F15/LAM4/KZN) family. Our study is 
in support of the above mentioned data as all the isolates belonging to F15 in this study were 
XDR. 
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The presence of the F11 family in our study is not a surprise as the isolate is known to have first 
been described in South Africa (Abadía et al. 2009) as explained earlier on in chapter one. This 
gives an impression that the F11 is well established in the country and is one of the families 
responsible for TB epidemic. From a study done in Cape Town (Victor et al. 2004), this family 
was the most predominant and was associated with drug resistant TB. It is considered to be one 
of the successful strains causing TB epidemic in the Western Cape. The fingerprints of the F11 
isolate also match the isolates identified in the database from Netherlands giving an indication 
that this family is also present in other countries and might have been imported from these 
countries. 
 
 
We found it difficult to compare our IS6110 RFLP results with some of the studies conducted 
within South African, the neibouring countries and the rest of African countries as it were the 
case with spoligotyping. In addition, through data search, it shows that TB molecular 
epidemiological studies targeting the IS6110 element are not commonly done in African as only 
few countries have presented their data. In South Africa, the molecular fingerprinting of MTB 
isolates through IS6110 RFLP is largely performed by at University of Stellenbosch Department 
of Molecular Biology and Human Genetics. This probably explains why most of the publications 
we currently have in South Africa are on the isolates from the Western Cape.  
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The lack of this procedure in many countries may be due to labour intensive nature of the 
procedure, its cost effectiveness and the lack of skills in the field. The other drawback was that 
some of the studies conducted so far did not use the Gelcompar software to analyze their results 
but rather used visual analysis (Green et al. 2013). In addition, classification of fingerprint 
patterns has been observed to be different from each study (Abbadi et al. 2001;  Green et al. 2013 
van Soolingen et al. 1993). This means that such isolates did not form part of the database to 
which the results presented here were analyzed.  Some studies used a different probe and a 
different restriction enzyme (Thierry et al. 1990) which had different restriction sites leading to 
different restriction fragments. However, the data presented here has shown the presence of 
predominant MTB isolates which are also in circulation elsewhere and highlights the benefits of 
using IS6110 for molecular typing of isolates.  
 
 
It was observed that the high incidence of the absence of our isolates from the database was 
mainly in terms of isolates with low copy number; orphan isolates and isolates lacking the 
element IS6110. Only two of the six low copy number isolates, were identified in the database 
while the remaining 5 isolates were absent. Similarly, none the orphan isolates were observed in 
the database. Only a single isolate with more than six IS6110 copy numbers was absent in the 
database but after counting the fingerprints, it was noticed to contain 7 fingerprints which is 
closer to six. The observation of poor discriminatory power by IS6110 RFLP in isolates 
containing IS6110 copy number of less than six, was also observed in a study done by Flores et 
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al. 2010 and recommended the use of secondary typing method to such MTB isolates. This shall 
mean that, from our study any isolate with higher copy number was able to or nearly match the 
fingerprints in the database.  
 
Though other studies have doubted the discriminating power of the spoligotyping technique, this 
study has demonstrated a good correlation between spoligotyping and IS6110 RFLP 
fingerprinting technique. We support the use of spoligotyping as an initial typing technique as 
recommended by Goyal & Saunders 1997 and  Warren et al. 2002. Spoligotyping can serve as a 
filtering technique to identify isolates that would benefit from further IS6110 RFLP typing and 
thereby minimizing both cost and turn-around-time 
 
With the limited sample size, the results presents here have demonstrated that isolates from the 
Johannesburg region are rich in molecular fingerprinting data and future studies should include 
these typing methods. It has further been shown that these isolates are not specific to the region 
but are also present in other provinces of South Africa and outside the South Africa borders. 
Frequencies of other isolate families such as Beijing and F15/LAM/KZN seem to be higher in 
Johannesburg than in other South African provinces. This is a major concern since the two 
families are highly associated with drug-resistance. Johannesburg is a highly industrialized and 
populated city whereby these conditions favour the spread of these families.  
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For future studies, we recommend IS6110 fingerprinting all the isolates enrolled in this study in 
order to have a true representation of the isolates circulating in the area as the sample size 
included was too small. We would also like to propose that further studies should be done on all 
the isolates which were classified as orphans by spoligotyping and failed to be identified by 
RFLP fingerprinting because the infectivity of these isolates in the community is not known.  
 
 
Finally, the study achieved its objectives to establish the RFLP procedure in the department and 
to compare subsets of isolates through the IS6110 RFLP database in order to determine the 
predominant families circulating in Johannesburg area. 
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Chapter four: Conclusion and recommendations 
 
 
This is the first molecular study to have typed the isolates of different susceptibility patterns 
from the great Johannesburg metropolitan area, through both spoligotyping and IS6110 RFLP.  
 
Spoligotyping of 500 isolates yielded 98 different patterns, of which 59 patterns from 458 
isolates were present in the Spoligotyping database 4 (SpoliDB4). This showed that 92% of our 
sample matched the pre-existing shared types in SpoliDB4. It was determined that eight families 
were predominant and these were; Beijing SIT 1, S SIT 34, LAM 4 SIT 60, T1 SIT 53, LAM3 
SIT 33, H3 SIT 50, EAI1-SOM SIT 48 and X3 SIT 92. The Beijing family was the most 
predominant and was almost equally distributed in all the seven regions of Johannesburg.  
 
The Beijing SIT 1 and LAM 4 SIT 60 families were both associated with drug-resistance. The 
LAM 4 isolates on the other note were highly associated with XDR-TB. There was no sensitive 
isolate observed in this family. Furthermore, the Beijing SIT 1 and LAM 4 SIT 60 seems to be 
more prevalent in South Africa than any other African country indicating geographical 
specificity of isolates. 
 
 
The analysis of 74 MTB isolates through IS6110 RFLP generated 30 distinct RFLP 
fingerprinting patterns. The IS6110 copy number ranged from 0 – 22. Sixty one isolates had their 
fingerprints available in the database while 13 isolates did not exist in the database. After 
classification of the isolates, it was revealed that strains from 12 families showed clustering. The 
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F29 family was found to be the most predominant by clustered with 12 isolates. The other 
clustering families were F15, F28, F31, F4, F2, F18, F9, FA, FB, FC and FD. The F29 and F31 
are interchangeably called Beijing family while F15 is interchangeably called LAM 4 SIT 60 
family. 
 
The combination of spoligotyping and IS6110 RFLP in the molecular typing of Mycobacterium 
tuberculosis is recommended. Discriminating powers differed mainly in isolates containing low 
copy number of IS6110 of six and less. Spoligotyping discriminated well all the isolates 
containing a low copy number of six and less while IS6110 RFLP showed poor discriminatory 
power. Despite this, the two methods showed a good correlation of the results with fifty six 
isolates having identical IS6110 RFLP patterns as well as spoligotypes.  
 
Not surprisingly the results showed that TB in Johannesburg is caused by different types of 
strains as there was no clonal circulation of the strain. However, the Beijing family seems to be 
well established and well represented in Johannesburg as it was the most predominant family in 
this study. In addition, LAM4 SIT 60 which is known as the KZN family is also in high 
circulation in the Johannesburg metropolitan area. Its frequencies were very high in XDR-TB 
confirming its association with drug-resistance.  
 
A high clustering rate of isolates was observed. This may possibly indicate a large scale 
transmission of TB taking place in Johannesburg and we therefore recommend that the National 
Tuberculosis Program evaluates its current control measures to minimize the spread of the 
disease.  
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Despite the limited sample size analyzed through IS6110 RFLP fingerprinting, this study has 
shed light on the fingerprint patterns of MTB isolates circulating in Johannesburg area. It is 
therefore recommended that after the initial typing of isolates through spoligotyping, further 
analysis should be done using IS6110 RFLP. Further analysis of the orphan isolates to determine 
strain properties such as infectivity, is also recommended. 
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Appendices 
 
Appendix 1: Ethical approval from the University of the Witwatersrand 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
118 
 
 
 
 
 
Appendix 2: Spoligotyping Solutions 
2A:         Stock solutions 
 
2A.1       20X SSPE 
 
 27.6g Sodium Hydrogen Phosphate (monohydrate) 
 175.3g Sodium Chloride 
 7.6g EDTA  
 dH2O 1000ml 
 Adjust pH to 7.4 
 Autoclave 
 Stable at room temperature for 1 year 
 
2A. 2     2X SSPE 
 
 Dilute 20X SSPE ten times with dH2O (1/10) 
 
 
2A.3     10X SSPE  
 
 13.8g Sodium Hydrogen Phosphate (monohydrate) 
 87.65g Sodium Chloride 
 3.8g EDTA 
 dH2O 1000nl 
 Adjust Ph to 7.4 
 Autoclave 
 Stable at room temperature for 1 year 
 
2A.4     10% SDS 
 
 50g SDS (Mix in fume Hood) 
 dH2O 500ml 
 
2A.5     0.5M EDTA 
 
 93g EDTA 
 dH20 500ml 
 
2A.6     Detection solution 1 & 2 (Amersham) 
 
 Ready for use 
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Appendix 2 continues: Spoligotyping solutions 
 
2B:    Working solutions 
 
2B.1     500ml 2X SSPE/0.1% SDS 
 
 100ml 10X SSPE 
 5ml 10% SDS 
 dH2O 500ml 
 
2B.2     500ml 2X SSPE/0.5% SDS 
 
 100ml 10X SSPE 
 25ml 10% SDS 
 dH20 500ml 
 
2B.3      200ml 1% SDS 
 
 20ml 10% SDS 
 dH2O 200ml 
 
2B.4      500ml 20 mM EDTA 
 
 20ml 0.5 EDTA 
 dH2O 500ml 
 pH 8 
 
2B.5     Detection solution 
 
 Prepare fresh solution each time 
 Mix equal volumes of detection solution 1 and 2 
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Appendix 3: Solutions for RFLP 
   
 
3A.       Lysozyme 
 
 Working [lysozyme]: 50mg/ml 
 Dissolve 500mg of lysozyme in 10ml of d    
 Store at - 20˚C 
 
3B.         RNAse A 
 
 working [RNaseA]: 10mg/ml 
 Dissolve 50mg of RNaseA in 5ml of 10mM Tris-HCl, pH 7.4; 15mM NaCl.  
 Heat at 100 ˚C for 15 minutes 
 Allow to cool slowly at room temperature and store in aliquots.  
 Store at -20 ˚C  
 
3C.      10X Proteinase K buffer pH 7.8 
 
 2.5g 5% SDS 
 5ml 100mM Tris-HCl pH 7.8 (from 1M stock) 
 5ml 50mM EDTA (from 0.5M stock) 
 Autoclave 
 Store at room temperature 
 
3D.        Chloroform: Isoamyl alcohol 
 
 384ml chloroform  
 16ml Isoamyl alcohol to make a 24:1 ratio 
 Invert to mix 
 Store between 2 and 8 degrees Celsius  
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Appendix 3continues: Solutions for RFLP 
 
 
3E.       3M Sodium Acetate pH 5.2 
 
 204.12 g Sodium acetate  
 Fill up with water to 400ml mark 
 Adjust pH to 5.2 with glacial acetic (approx 60ml) 
 Autoclave 
 Store at room temperature 
 
3F.     TE buffer pH 8.0 
 
 1.211g 10mM Tris 
 0.372g 1mM EDTA 
 Fill up to 1L with dH2O 
 Adjust pH to 8  
 Autoclaving. 
 Store at room temperature 
 
3G.    1X Restriction Buffer (NEBuffer 2) pH 7.9 
 
 50 mM NaCl 
 10 mM Tris-HCl 
 10 mM MgCl2 
  1 mM DTT 
 Store at 25 °C  
 Supplied as a 10X concentrated stock. 
 
3H.      6X Loading Buffer 
 
 60mg bromophenol blue 
 0.6g sodium dodecyl sulfate 
 Fill to 70mL with ddH20 and swirl to mix 
 Add 30mL of 100% gylcerol and swirl to mix 
 Store at room temperature 
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Appendix 3continues: Solutions for RFLP 
 
 
3I.        10X TBE buffer pH 8.3 
 
 108g Tris 
 55g Boric Acid 
 7.44g EDTA 
 Fill to 1000mL with ddH2O 
 Add stirrer bar and place on stirrer to dissolve solutes 
 Autoclave 
 Store at room temperature 
 
3J.         Internal Molecular Weight Marker 
 
 6 ml TE pH 8.0 
 2 ml loading buffer 
 6.6 μl Marker X 
 Mix eppendorf tube by inversion 
 Store at -20 degrees Celsius 
 
3K.       Denaturing Buffer 
 
 87,66g 1.5M NaCl  
 20g 0.5M NaOH 
 Fill up to 1L with dH2O 
 Add stirrer bar and place on stirrer to dissolve solutes 
 Autoclave 
 Store at room temperature 
 
3L.        Neutralizing Buffer 
 
 87.66g 1.5M NaCl (use stirring bar to dissolve it) 
 60.5g 0.5M Tris-HCl pH 7.5 
 Fill up to 1L with dH20 
 Add stirrer bar and place on stirrer to dissolve solutes 
 Autoclave 
 Store at room temperature 
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Appendix 3continues: Solutions for RFLP 
 
3M.      Orientation Marker 
 
 2µl Marker X (250 ng/µl)  
 20µl MTBC 14323 DNA (1.25µg/µl), 
 45µl 0.8 M NaOH, 
 23µl TE (pH 8.0) 
 
3N.    20X SSPE Solution pH 7.4 
 
 175.3g of NaCl 
 27.6g of NaH₂PO₄-H₂O 
 7.6 g of EDTA 
 Add 800ml dH₂0 
 Adjust the pH to 7.4  
 Adjust the volume to 1l with additional distilled H₂O. 
 Autoclave 
 
3O.   20X SSC Solution pH 7. 
 Dissolve the following in 800ml of distilled H₂O. 
 175.3g of NaCl 
 88.2g of sodium citrate 
 Adjust the pH to 7.0 with a few drops of 1M HCl. 
 Adjust the volume to 1l with additional distilled H₂O. 
 Autoclave 
 
3P.     Primary Wash Buffer 
 
 720g urea 
  8g sodium dodecyl sulphate (SDS) 
 Make up to 2l with distilled water. 
 Autoclave 
 
3Q.     1% SDS 
 
 5g SDS 
 dH₂O 500ml  
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 Place on shaker with stirrer bar to dissolve 
 
 
 
Appendix 3continues: Solutions for RFLP 
 
 
3R.     5M Nacl 
 584g NaCl dH2O to 2000ml  
 Place on shaker with stirrer bar to dissolve 
  Autoclave. 
 
3S.     70% Ethanol 
 
 70ml of absolute Ethanol  
 dH2O 100ml 
 
 
3T.     CTAB/ NaCl 
 10g CTAB + 4.1g NaCl,  
 dH2O to 80ml,  
 dissolve at 65˚C 
 Adjust volume to 100ml with dH2O. 
 Store at room temperature. 
 
3U.   ECL Hybridization buffer 
 100ml ECL hybridization buffer,  
 5.844g NaCl final concentration 0.5M 
 5g blocking reagent: final concentration of 5% (w/v).  
 Add the blocking reagent slowly to the buffer solution while stirring. 
 Continue mixing at RT for 1h on a magnetic stirrer, then heat to 42˚C for 30 to 60 
minutes with occasional mixing.  
 Store at -20˚C for three months 
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